PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 15/00

A2

(11) International Publication Number: WO 00/61736

(43) International Publication Date: 19 October 2000 (19.10.00)

(21) International Application Number: PCT/US00/09518

(22) International Filing Date: 7 April 2000 (07.04.00)

(30) Priority Data:
09/289,254 9 April 1999 (09.04.99) US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application
US 09/289,254 (CON)
Filed on 9 April 1999 (09.04.99)

(71) Applicant *(for all designated States except US)*: SCHERING–PLOUGH LTD. [CH/CH]; Toepferstrasse 5, CH–6004 Lucerne (CH).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: JUNKER, David, E. [US/US]; 6901 Galewood Street, San Diego, CA 92120 (US).

(74) Agents: FOULKE, Cynthia, L. et al.; Schering–Plough Corporation, Patent Dept. K–6–1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033–0530 (US).

(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: NOVEL RECOMBINANT AND MUTANT HERPESVIRUSES

(57) Abstract

The present invention provides methods and reagents for inducing active immunity in animals. In particular, the present invention provides recombinant herpesviruses having foreign DNA that are capable of inducing immunity to the herpesvirus and/or the source of the foreigh DNA. The present invention also provides mutant herpesviruses having portions of their genome deleted. Preferably, foreign DNA is introduced, or portions of the genome are deleted, in the UL54.5 open reading frame of avian herperviruses or the UL43 open reading frame of Marek's disease virus.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

NOVEL RECOMBINANT AND MUTANT HERPESVIRUSES

Field Of The Invention

The present invention relates to viral vectors for vaccination of animals. In particular, the present invention pertains to viral vectors having gene insertion sites for the introduction of foreign DNA.

Background Of The Invention

Marek's disease is a lymphoproliferative disease of chickens caused by Marek's disease virus (MDV). MDV, a naturally occurring herpesvirus, infects bursa-derived and thymus-derived lymphocytes in chickens, and may subsequently induce a lymphoma of thymus-derived lymphocytes. MDV is a designation of a family of avian herpesviruses. For example, MDV1 is a virulent strain of herpesvirus in chickens, MDV2 is a naturally attenuated herpesvirus strain in chickens, and MDV3 is a nonpathogenic herpesvirus of turkey.

Since Marek's disease is contagious, the virus has become an important pathogen of chickens, particularly in an environment of large-scale breeding such as in the poultry industry. Currently, Marek's disease is controlled by vaccination of embryos at 17-19 days of incubation, or one-day-old chicks.

The application of recombinant DNA techniques to animal viruses in general has a recent history. The first viruses to be engineered have been those with the smallest genomes. For example, in the case of the papovaviruses, because these viruses are so small and cannot accommodate much extra DNA, their use in genetic engineering has been as defective replicons. Thus, foreign DNA sequence expression from these viruses requires a wild-type helper virus and is limited to cell culture systems. On the other hand, for adenoviruses, there is a small amount of nonessential DNA that can be replaced by foreign sequences. This technique has also been applied to portions of the herpesvirus genome in an avian herpesvirus (see U.S. Patent No. 5,853,733 to Cochran et al).

The cases of deletion or insertion of genes into herpesviruses demonstrate that it is possible to genetically engineer herpesvirus genomes by recombinant DNA techniques. In the past, the methods that have been used to insert genes involve homologous recombination between the viral DNA cloned in plasmids and purified viral DNA transfected into the same animal cell. However, the extent to which one can generalize the location of the deletion and the sites for insertion of foreign DNA sequences is not known from these previous studies.

The identification of suitable DNA sequence insertions sites in avian herpesviruses are valuable for the development of new vaccines. The selection of (i) a suitable virus and (ii) the particular portion of the genome to use as an insertion site for creating a vector for foreign DNA sequence expression, however, pose a significant challenge. In particular, the insertion site must be non-essential for the viable replication of the virus, as well as its operation in tissue culture and *in vivo*. Moreover, the insertion site must be capable of accepting new genetic material, while ensuring that the virus continues to replicate.

What is needed is the identification of novel viruses and gene insertion sites for the creation of new viral vectors.

Summary Of The Invention

The present invention provides mutant and recombinant herpesviruses comprising a foreign DNA sequence inserted into a site in the herpesvirus genome. In one embodiment, the site is non-essential for viral replication. In a preferred embodiment, the foreign DNA sequence is capable of being expressed in a host cell infected with the recombinant herpesvirus and its expression. In a particularly preferred embodiment, the foreign DNA sequence is also under control of a promoter located upstream of the foreign DNA sequence.

The present invention is not limited to particular sites for insertion or deletion. In one embodiment, the deletion and/or insertion is in the UL54.5 open reading frame of a Marek's disease virus. In another embodiment, the deletion and/or insertion is in the UL43 open reading frame of a Marek's disease virus. In

a preferred embodiment, the insertion is in the genome of Marek's disease virus type 1.

While not limited to particular types of DNA inserted, in one embodiment of the present invention the foreign DNA sequence inserted into the herpesvirus genome encodes a polypeptide. Preferably, the polypeptide is immunogenic to the animal into which the recombinant herpesvirus is introduced. Preferably, this immunogenic polypeptide is a linear polymer of more than 10 amino acids linked by peptide bonds which stimulates the animal to produce antibodies. In a preferred embodiment, the foreign DNA sequence also encodes a detectable marker. Preferably, the detectable marker is *E. coli* B-galactosidase.

In preferred embodiments, the recombinant herpesvirus contains a foreign DNA sequence encoding an immunogenic polypeptide from chicken anemia virus (CAV), infectious bursal disease virus (IBDV), Marek's disease virus (MDV), Newcastle disease virus (NDV), infectious laryngotracheitis virus (ILTV), or infectious bronchitis virus (IBV), fragments thereof and/or substantially homologous sequences. In another preferred embodiment, the foreign DNA encodes a cytokine. The present invention also contemplates recombinant herpesviruses having more than one foreign DNA sequence encoding an antigen or antigens.

When the foreign DNA sequence of the recombinant herpesvirus of the present invention encodes an immunogenic polypeptide from infectious bursal disease virus (IBDV), it is preferred that the immunogenic polypeptide is IBDV VP2, VP3 or VP4 protein, fragments thereof and/or substantially homologous sequences. When the foreign DNA sequence encodes an immunogenic polypeptide from MDV. Preferably, the immunogenic polypeptide is MDV glycoprotein B (gB), glycoprotein D (gD), or glycoprotein A (gA) fragments thereof and/or substantially homologous sequences.

When the foreign DNA sequence encodes an immunogenic polypeptide from Newcastle disease virus (NDV), it is preferred that the immunogenic polypeptide is NDV fusion (F) protein or NDV hemagglutinin-neuraminidase (HN), fragments thereof and/or substantially homologous sequences.

When the foreign DNA sequence encodes an immunogenic polypeptide from infectious laryngotracheitis virus (ILTV), it is preferred that the immunogenic polypeptide is ILTV glycoprotein "B" (gB), ILTV glycoprotein D (gD), or ILTV glycoprotein I (gI), fragments thereof and/or substantially homologous sequences.

When the foreign DNA sequence encodes an immunogenic polypeptide from infectious bronchitis virus (IBV), it is preferred that the immunogenic polypeptide is IBV spike protein, IBV matrix protein, nucleocapsid protein, fragments thereof and/or substantially homologous sequences.

The expression of the inserted foreign DNA sequence can be under control of a promoter located upstream of the foreign DNA sequence. Preferably, the promoter is a herpesvirus promoter. More preferably, the promoter is selected from a group consisting of pseudorabies virus (PRV) gX promoter, MDV gB promoter, MDV gA promoter, MDV gD promoter, ILTV gB promoter, ILTV gD promoter, ITLV gI promoter, human cytomegalovirus virus (HCMV) immediate early promoter, and/or substantially homologous sequences.

The present invention further provides for a homology vector for producing a recombinant herpesvirus by inserting a foreign DNA sequence into the herpesvirus genome. In one embodiment, the homology vector comprises a double-stranded DNA molecule consisting essentially of a double-stranded foreign DNA sequence, with at one end of the foreign DNA sequence, double-stranded DNA homologous to the genomic DNA located at one side of a non-essential site of the herpesvirus genome, and at the other end of the foreign DNA sequence, double-stranded DNA homologous to the herpesvirus genomic DNA sequence located at the other side of the same site. In such an embodiment, the double-stranded DNA can be homologous to a DNA sequence present within a 3212 base pair *Sac*I to *Bgl*II subfragment contained within the *Bam*HI "B" genomic fragment of a Marek's disease virus type 1. Preferably, a DNA sequence corresponding to a promoter is located upstream of the foreign DNA sequence and controls its expression. Likewise, it is preferable that the foreign DNA sequence encode an immunogenic polypeptide (e.g. those described above).

In one embodiment of the invention, the double-stranded herpesvirus DNA is homologous to DNA sequence present within the *Bam*HI "B" fragment of the MDV herpesvirus genome. Preferably, the double-stranded herpesvirus DNA is homologous to DNA sequences present within the open reading frame encoding UL 43 protein of the herpesvirus genome. In another embodiment of the invention, the double-stranded herpesvirus DNA is homologous to DNA sequences present within the *Bam*HI "M" fragment of a herpesvirus genome. Preferably, the double-stranded herpesvirus DNA is homologous to DNA sequence present within the UL54.5 gene coding region of a herpesvirus genome.

The invention further provides a vaccine which comprises an effective immunizing amount of a recombinant or mutant herpesvirus of the present invention and a suitable carrier.

The present invention further provides a method of immunizing an animal. A preferred animal to be immunized is a fowl.

The present invention also provides a method of immunizing a fowl *in ovo*. For the purposes of this invention, this includes immunizing a fowl against infectious bursal disease virus, Marek's disease virus, Newcastle disease virus, infectious laryngotracheitis virus, or infectious bronchitis virus. Preferably, the method comprises administering to the fowl an effective immunizing dose of the vaccine of the present invention. The vaccine may be administered by any of the methods well known to those skilled in the art, for example, by intramuscular, subcutaneous, intraperitoneal or intravenous, injection. Alternatively, the vaccine may be administered intranasally, orally or intraocularly.

The present invention also provides a host cell infected with a recombinant herpesvirus of the present invention. Preferably, the host cell is an avian cell.

Definitions

For purposes of this invention, a "host cell" is a cell used to propagate a vector and its insert. Infecting the cell can be accomplished by methods well known to those skilled in the art, for example, as set forth in DNA Transfection For Generating Recombinant Herpesvirus 11) below.

The term, "animal" refers to organisms in the animal kingdom. Thus, this term includes humans, as well as other organisms. Preferably, the term refers to vertebrates. More preferably, the term refers to avian animals.

An "effective immunizing amount" of recombinant herpesvirus of the present invention is within the range of 10^2 to 10^9 Plaque Forming Units (PFU)/dose.

For purposes of this invention, a "homology vector" is a plasmid constructed to insert foreign DNA sequence in a specific site on the genome of a herpesvirus.

A "foreign DNA sequence" is a segment of DNA that has been or will be attached to another DNA molecule using recombinant techniques wherein that particular DNA segment is not found in association with the other DNA molecule in nature. The source of such foreign DNA may or may not be from a separate organism than that in which it is placed. The foreign DNA may also be a synthetic sequence having codons different from the native gene. Examples of recombinant techniques include, but are not limited to, the use of restriction enzymes and ligases to splice DNA.

An "insertion site" is a restriction site in a DNA molecule into which foreign DNA can be inserted.

A "replication competent virus" is a virus whose genetic material contains all of the DNA or RNA sequences necessary for viral replication as are found in a wild-type of the organism. Thus, a replication competent virus does not require a second virus or a cell line to supply something defective in or missing from the virus in order to replicate. A "non-essential site in the herpesvirus genome" means a region in the herpesvirus genome, the polypeptide product of which is not necessary for viral infection or replication.

A "vector" is a replicon, such as a plasmid, phage, cosmid or virus, to which another DNA sequence may be attached so as to bring about the expression of the attached DNA sequence.

A "double-stranded DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its normal,

double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found in linear DNA molecules (e.g., restriction fragments of DNA from viruses, plasmids, and chromosomes).

A DNA "coding sequence" is a DNA sequence which is transcribed and translated into a polypeptide *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A coding sequence can include, but is not limited to, procaryotic sequences, cDNA from eucaryotic mRNA, genomic DNA sequences from eucaryotic (e.g., mammalian) DNA, viral DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence can be located 3' to the coding sequence.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase or an auxiliary protein in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is in close proximity to the 3' terminus by the translation start codon (ATG) of a coding sequence and extends upstream (5' direction) to include the minimum number of bases or elements necessary to facilitate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site, as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eucaryotic promoters will often, but not always, contain "TATA" boxes and "CAAT" boxes, conserved sequences found in the promoter region of many eucaryotic organisms.

A coding sequence is "operably linked to" or "under the control of" control sequences in a cell when RNA polymerase will interact with the promoter sequence directly or indirectly and result in the transcription of the coding sequence into mRNA, which is then translated into the polypeptide encoded by the coding sequence.

Two polypeptide sequences are "substantially homologous" when at least about 80% (preferably at least about 90%, and most preferably at least about 95%) of the amino acids match over a defined length of the molecule.

Two DNA sequences are "substantially homologous" when they are identical to or not differing in more that 40% of the nucleotides, more preferably about 20% of the nucleotides, and most preferably about 10% of the nucleotides.

A virus that has had a foreign DNA sequence inserted into its genome is a "recombinant virus," while a virus that has had a portion of its genome removed by intentional deletion (*e.g.*, by genetic engineering) is a "mutant virus."

The term "polypeptide" is used in its broadest sense, i.e., any polymer of amino acids (dipeptide or greater) linked through peptide bonds. Thus, the term "polypeptide" includes proteins, oligopeptides, protein fragments, analogs, muteins, fusion proteins and the like.

"Antigenic" refers to the ability of a molecule containing one or more epitopes to stimulate an animal or human immune system to make a humoral and/or cellular antigen-specific response. An "antigen" is an antigenic polypeptide.

An "immunological response" to a composition or vaccine is the development in the host of a cellular and/or antibody-mediated immune response to the composition or vaccine of interest. Usually, such a response consists of the subject producing antibodies, B cells, helper T cells, suppressor T cells, and/or cytotoxic T cells directed specifically to an antigen or antigens included in the composition or vaccine of interest.

The terms "immunogenic polypeptide" and "immunogenic amino acid sequence" refer to a polypeptide or amino acid sequence, respectively, which elicit antibodies that neutralize viral infectivity, and/or mediate antibody-complement or antibody dependent cell cytotoxicity to provide protection of an immunized host. An "immunogenic polypeptide" as used herein, includes the full length (or near full length) sequence of the desired protein or an immunogenic fragment thereof.

By "immunogenic fragment" is meant a fragment of a polypeptide which includes one or more epitopes and thus elicits antibodies that neutralize viral

infectivity, and/or mediates antibody-complement or antibody dependent cell cytotoxicity to provide protection of an immunized host. Such fragments will usually be at least about 5 amino acids in length, and preferably at least about 10 to 15 amino acids in length. There is no critical upper limit to the length of the fragment, which could comprise nearly the full length of the protein sequence, or even a fusion protein comprising fragments of two or more of the antigens.

By "infectious" is meant having the capacity to deliver the viral genome into cells.

The term "open reading frame" or "ORF" is defined as a genetic coding region for a particular gene that, when expressed, can produce a complete and specific polypeptide chain protein.

The term "avian herpesvirus" connotes a herpesvirus that is capable of replicating in avian hosts and do not naturally replicate in other host animals.

Brief Description of the Drawings

Figure 1 is a *Bam*H1 restriction map of an MDV genome particularly pointing out the location of an "M" fragment.

Figure 2 is a map designating the open reading frames in the *Bam*H1 "M" fragment of an MDV genome.

Figure 3 is a *Bam*H1 restriction map of an MDV genome particularly pointing out the location of *Sac*I-*Bgl*III fragments.

Figure 4 is a map designating the open reading frames in the *Sac*I-*Bgl*III fragment of an MDV genome.

Figure 5 is a *Bam*H1 restriction map of an MDV genome particularly pointing out the location of a "G" fragment.

Figure 6 is a map of the open reading frames in the *Bam*HI "G" fragment of an MDV genome.

Detailed Description Of The Invention

Throughout this disclosure, various publications, patents and patent applications are referenced. The disclosures of these publications, patents and patent applications are herein incorporated by reference.

The methods and compositions of the present invention involve modifying cloned DNA sequences from various prokaryotic and eucaryotic sources and by insertions, deletions, single or multiple base changes, and subsequent insertions of these modified sequences into the genome of a herpesvirus. One example includes cloning parts of a herpesvirus DNA into plasmids in bacteria, reconstructing the virus DNA while in the cloned state so that the DNA contains deletions of certain sequences, and/or furthermore adding foreign DNA sequences either in place of the deletions or at sites removed from the deletions. The methods and compositions of the present invention also involve the deletion of a portion of the genome of a herpesvirus to produce a mutant virus.

Generally, the foreign gene construct is cloned into a nucleotide sequence which represents only a part of the entire herpesvirus genome, which may have one or more appropriate deletions. This chimeric DNA sequence is usually present in a plasmid which allows successful cloning to produce many copies of the sequence. The cloned foreign gene construct can then be included in the complete viral genome, for example, by *in vivo* recombination following a DNA-mediated cotransfection technique. Multiple copies of a coding sequence or more than one coding sequences can be inserted so that the recombinant vector can express more than one foreign protein. The foreign gene can have additions, deletions or substitutions to enhance expression and/or immunological effects of the expressed protein.

In order for successful expression of the gene to occur, it can be inserted into an expression vector together with a suitable promoter including enhancer elements and polyadenylation sequences. A number of eucaryotic promoter and polyadenylation sequences which provide successful expression of foreign genes in mammalian cells and how to construct expression cassettes, are known in the art, for example in U.S. Pat. No. 5,151,267. The promoter is selected to give

optimal expression of immunogenic protein which in turn satisfactorily leads to humoral, cell mediated and mucosal immune responses according to known criteria.

The foreign protein produced by expression *in vivo* in a recombinant virus-infected cell may be itself immunogenic. More than one foreign gene can be inserted into the viral genome to obtain successful production of more than one effective protein.

Therefore, one utility of the use of a mutant herpesvirus or the addition of a foreign DNA sequence into the genome of a herpesvirus is to vaccinate an animal. For example, a mutant virus could be introduced into an animal to elicit an immune response to the mutant virus.

Alternatively, a recombinant herpesvirus having a foreign DNA sequence inserted into its genome that encodes a polypeptide may also serve to elicit an immune response in an animal to the foreign DNA sequence, polypeptide encoded by the foreign DNA sequence and/or herpesvirus. Such a virus may also be used to introduce foreign DNA and its products into the host animal to alleviate a defective genomic condition in the host animal. These recombinant herpesviruses are referred to as viral vectors when it is a virus that can carry the foreign DNA in the host animal.

The present invention is not limited to the use of a particular herpesvirus vector. One avian herpesvirus suitable for use as a viral vector is MDV. To provide for MDV as a vector and vaccine against Marek's Disease, it is desirable to locate a site within the MDV genome which is not essential for viral replication and function; and into which can be inserted one or more endogenous genes encoding an MDV antigen(s) to further stimulate the immune response against the encoded antigen(s). On the other hand, to provide for MDV as a viral vector or as an expression vector for use as a multivalent vaccine, it is desirable to locate a site within the MDV genome which is not essential for viral replication and function; and into which can be inserted one or more exogenous genes encoding an antigen(s) of a poultry pathogen other than MDV to further stimulate the immune response against MDV and such other poultry pathogens. Alternatively, a

combination of copies of endogenous genes and exogenous genes may be inserted into a nonessential region of such viral vector.

When an MDV genome is used, it is preferred that an attenuated MDV type 1 strain be used. Rispens CVI-988 is an attenuated serotype 1 MDV vaccine strain that can be used to provide protection against very virulent strains of MDV.

This MDV genome is a linear 180 kilobase pair double stranded molecule consisting of two unique regions: a unique short region (US), and a unique long region (UL). Each of the unique regions is flanked by inverted repeats: a long terminal repeat (TRL) and internal long inverted repeat (IRL) for UL, and a short internal inverted repeat (IRS) and short terminal repeat (TRS) for US.

While the present invention is not limited to particular DNA deletion and/or insertion sites, it has been discovered that the UL43 region and UL54.5 region of avian herpesviruses contain appropriate sites for deletion and insertion. For example, there is an *Xho*I site within the UL43 region of avian herpesviruses, and in particular within the MDV genome. There is also an open reading frame (ORF) that is flanked by the UL54 and UL55 regions. This ORF, designated as UL54.5, contains an *Nde*I site suitable for deletion and insertion.

In particular, there is a 3212 base pair *Sac*I to *Bgl*II subfragment contained within the *Bam*HI "B" genomic fragment of Marek's disease virus type 1. A preferred deletion and/or insertion site within the 3212 base pair *Sac*I to *Bgl*II subfragment contained within the *Bam*HI "B" genomic fragment lies within an open reading frame encoding herpesvirus UL43 and a preferred insertion site insertion site within that open reading frame is a *Xho*I restriction endonuclease site.

Likewise, deletions and/or insertions can be placed in the *Bam*HI "M" genomic fragment of the herpesvirus genome. A preferred insertion site within *Bam*HI "M" genomic fragment lies within an open reading frame encoding herpesvirus UL54.5 and a preferred insertion site insertion site within that open reading frame is a *Nde*I restriction endonuclease site. In a particularly preferred embodiment, the product of the UL54.5 open reading frame is nonessential for viral replication.

Various foreign DNA sequences or coding sequences (viral, prokaryotic, and eucaryotic) can be inserted in the herpesvirus nucleotide sequence, e.g., DNA, in accordance with the present invention, particularly to provide protection against a wide range of diseases and many such genes are already known in the art. While not limited to any particular foreign DNA sequence, typically the foreign DNA sequence of interest will be derived from pathogens that in avian cause diseases that have an economic impact on the poultry industry. The genes may be derived from organisms for which there are existing vaccines, and because of the novel advantages of the vectoring technology the herpesvirus derived vaccines will be superior. Also, the gene of interest may be derived from pathogens for which there is currently no vaccine but where there is a requirement for control of the disease. Typically, the gene of interest encodes immunogenic polypeptides of the pathogen, and may represent surface proteins, secreted proteins and structural proteins.

A relevant avian pathogen that is a target for herpesvirus vectoring is Infectious Laryngotracheitis virus (ILTV). ILTV is a member of the herpesviridiae family, and this pathogen causes an acute disease of chickens which is characterized by respiratory depression, gasping and expectoration of bloody exudate.

Another target for the herpesvirus vectoring approach is Newcastle disease, an infectious highly contagious and debilitating disease that is caused by the Newcastle disease virus (NDV). NDV is a single-stranded RNA virus of the paramyxovirus family. The various pathotypes of NDV (velogenic, mesogenic, lentogenic) differ with regard to the severity of the disease, the specificity and symptoms, but most types seem to infect the respiratory system and the nervous system. NDV primarily infects chickens, turkeys and other avian species.

The present invention is also not limited to the use of a particular DNA sequence from an organism. Often selection of the foreign DNA sequence for insertion into a herpesvirus genome is based upon the protein it encodes. Preferably, the foreign DNA sequence encodes an immunogenic polypeptide. The preferred immunogenic polypeptide to be expressed by the virus systems of the

present invention contain full-length (or near full-length) sequences encoding antigens. Alternatively, shorter sequences that are immunogenic (i.e., encode one or more epitopes) can be used. The shorter sequence can encode a neutralizing epitope, which is defined as an epitope capable of eliciting antibodies that neutralize virus infectivity in an *in vitro* assay. Preferably the peptide should encode a protective epitope that is capable of raising in the host an protective immune response; i.e., an antibody- and/or a cell-mediated immune response that protects an immunized host from infection. In some cases the gene for a particular antigen can contain a large number of introns or can be from an RNA virus, in these cases a complementary DNA copy (cDNA) can be used.

It is also possible that only fragments of nucleotide sequences of genes can be used (where these are sufficient to generate a protective immune response) rather than the complete sequence as found in the wild-type organism. Where available, synthetic genes or fragments thereof can also be used. However, the present invention can be used with a wide variety of genes, fragment and the like, and is not limited to those set out herein.

Thus, the antigens encoded by the foreign DNA sequences used in the present invention can be either native or recombinant immunogenic polypeptides or fragments. They can be partial sequences, full-length sequences, or even fusions (e.g., having appropriate leader sequences for the recombinant host, or with an additional antigen sequence for another pathogen).

In a preferred embodiment, the mutant viruses and viral vectors of the present invention are replication competent. In this manner, the deletion from and/or insertion into the herpesvirus gnome does not destroy its ability to replicate. However, if the deletion and/or insertion does destroy or significantly inhibit the ability of the herpesvirus to replicate, the present invention contemplates the use of recombinant cell lines by constructing an expression cassette comprising a herpesvirus of the present invention and transforming host cells therewith to provide cell lines or cultures expressing proteins encoded by the deleted or disrupted DNA sequences.

These recombinant cell lines are capable of allowing a recombinant herpesvirus that is not replication competent to replicate and express the desired foreign DNA sequence or fragment thereof which is encoded within the recombinant herpesvirus. These cell lines are also extremely useful in generating recombinant herpesvirus, by *in vivo* recombination following DNA-mediated cotransfection.

When the methods and compositions of the present invention are used for vaccination, it is not limited to any particular administration. One example is parenteral administration. When administered parenterally, the vaccines can include the use of a vaccine carrier. Vaccine carriers are well known in the art: for example, bovine serum albumin (BSA), human serum albumin (HSA) and keyhole limpet hemocyanin (KLH). A preferred carrier protein, rotavirus VP6, is disclosed in European Patent Pub. No. 0259149.

The vaccines can also be orally administered in a suitable oral carrier, such as in an enteric-coated dosage form. Oral formulations include such normally-employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin cellulose, magnesium carbonate, and the like. Oral vaccine compositions may be taken in the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders, containing from about 10% to about 95% of the active ingredient, preferably about 25% to about 70%. An oral vaccine may be preferable to raise mucosal immunity in combination with systemic immunity, which plays an important role in protection against pathogens infecting the gastrointestinal tract.

In addition, the vaccine be formulated into a suppository. For suppositories, the vaccine composition will include traditional binders and carriers, such as polyalkaline glycols or triglycerides. Such suppositories may be formed from mixtures containing the active ingredient in the range of about 0.5% to about 10% (w/w), preferably about 1% to about 2%.

Protocols for administering to animals the vaccine composition(s) of the present invention are within the skill of the art in view of the present disclosure. Those skilled in the art will select a concentration of the vaccine composition in a

dose effective to elicit an antibody and/or T-cell mediated immune response to the immunogenic fragment. Within wide limits, the dosage is not believed to be critical.

Typically, the vaccine composition is administered in a manner which will deliver between about 1 to about 1,000 micrograms of the subunit antigen in a convenient volume of vehicle, e.g., about 1-10 cc. Preferably, the dosage in a single immunization will deliver from about 1 to about 500 micrograms of subunit antigen, more preferably about 5-10 to about 100-200 micrograms (e.g., 5-200 micrograms).

The timing of administration may also be important. For example, a primary inoculation preferably may be followed by subsequent booster inoculations if needed. It may also be preferred, although optional, to administer a second, booster immunization to the animal several weeks to several months after the initial immunization. To insure sustained high levels of protection against disease, it may be helpful to readminister a booster immunization to the animals at regular intervals, for example once every several years. Alternatively, an initial dose may be administered orally followed by later inoculations, or vice versa. Preferred vaccination protocols can be established through routine vaccination protocol experiments.

A recombinant herpesvirus of the present invention can also provide a way for distinguishing an animal vaccinated with the vaccine of the present invention from an animal infected with a naturally-occurring, wild-type infectious herpesvirus or other pathogen. This is possible because recombinant herpesvirus contain foreign DNA which encodes a limited number of antigens from the above mentioned viruses that are needed to confer protective immunity to the corresponding pathogens. Consequently, host animals vaccinated with those recombinant herpesviruses can be distinguished from ones which have been infected with wild-type infectious bursal disease virus, Marek's disease virus, Newcastle disease virus, infectious laryngotracheitis virus, or infectious bronchitis virus by the absence of antigens that are normally present in the wild type viruses. Moreover, when the herpesvirus vector contains a deletion of a portion of its

genome that encodes an immunogenic polypeptide, the lack of an immune response from the vaccinated animal to the product of the deleted portion will indicate a vaccinated animal.

The invention also includes a method for providing gene therapy to an animal in need thereof to control a gene deficiency which comprises administering to said animal a live recombinant herpesvirus containing a foreign nucleotide sequence encoding a non-defective form of said gene under conditions wherein the recombinant virus vector genome is incorporated into said mammalian genome or is maintained independently and extrachromosomally to provide expression of the required gene in the target organ or tissue.

These kinds of techniques are used by those of skill in the art to replace a defective gene or portion thereof. For example, U.S. Patent No. 5,399,346 to Anderson et al describes techniques for gene therapy. Moreover, examples of foreign DNA sequences nucleotide sequences or portions thereof that can be incorporated for use in a conventional gene therapy include, cystic fibrosis transmembrane conductance regulator gene, human minidystrophin gene, alphal-antitrypsin gene and the like.

Methods for constructing, selecting and purifying recombinant herpesvirus are detailed below in the Examples below. The following examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.

EXAMPLES

Example 1

Preparation Of Marek's Disease Virus (MDV-1) Stock

Marek's disease virus stock samples were prepared by infecting tissue culture cells at a multiplicity of infection of 0.01 PFU/cell in a 1:1 mixture of HAM'S F10 and 199 medium containing 2 mM glutamine, 100 units/ml penicillin, 100 units/ml streptomycin (these components are obtained from Sigma or an equivalent supplier, and hereafter are referred to as complete DME medium)

plus 1% fetal bovine serum. After cytopathic effect was complete, the medium and cells were harvested and the cells were pelleted at 3000 rpm for 5 minutes in a clinical centrifuge. Infected cells were resuspended in complete medium containing 20% fetal bovine serum, 10% DMSO and stored frozen at -70 °C.

Example 2

Preparation Of Marek's Disease Virus (MDV-1) DNA

All manipulations of Marek's disease virus were made using strain GA5 (ATCC #624) or Rispens CVI-988 (Vineland Labs). For the preparation of MDV viral DNA from the cytoplasm of infected cells, primary chicken embryo fibroblasts were infected at a MOI sufficient to cause extensive cytopathic effect before the cells overgrew. All incubations were carried out at 39 °C in a humidified incubator with 5% CO_2 in air. Best DNA yields were obtained by harvesting monolayers which were maximally infected, but showing incomplete cell lysis (typically 5-7 days). Infected cells were harvested by scraping the cells into the medium using a cell scraper. The cell suspension was centrifuged at 3000 rpm for 10 minutes at 5 °C in a GS-3 rotor.

The resultant pellet was resuspended in cold PBS (20 ml/roller bottle) and subjected to another centrifugation for 10 minutes at 3000 rpm in the cold. After decanting the PBS, the cellular pellet was resuspended in 4 ml/roller bottle of RSB buffer (10 mM Tris pH 7.5, 1 mM EDTA, and 1.5 mM $MgCl_2$). NP40 (Nonidet P-40; Sigma) was added to the sample to a final concentration of 0.5% minutes with occasional mixing. The sample was centrifuged for 10 minutes at 3000 rpm in the cold to pellet the nuclei and remove cellular debris. The supernatant fluid was carefully transferred to a 15 ml Corex centrifuge tube. Both EDTA (0.5M pH 8.0) and SDS (sodium dodecyl sulfate; stock 20%) were added to the sample to final concentrations of 5 mM and 1%, respectively. One hundred microliters of proteinase-K (10 mg/ml; Boehringer Mannheim) was added per 4 ml of sample, mixed, and incubated at 45 °C for 1-2 hours. After this period, an equal volume of water-saturated phenol was added to the sample and gently mixed by hand. The sample was spun in a clinical centrifuge for 5 minutes at 3000 rpm

to separate the phases. NaAc was added to the aqueous phase to a final concentration of 0.3M (stock solution 3M pH 5.2), and the nucleic acid precipitated at -70 °C for 30 minutes after the addition of 2.5 volumes of cold absolute ethanol. DNA in the sample was-pelleted by spinning for 20 minutes to 8000 rpm in an HB-4 rotor at 5 °C. The supernatant was carefully removed and the DNA pellet washed once with 25 ml of 80% ethanol. The DNA pellet was dried briefly by vacuum (2-3 minutes), and resuspended in 50 microliters/roller bottle of infected cells of TE buffer (10 mM Tris pH 7.5, 1 mM EDTA). Typically, yields of viral DNA ranged between 5-10 micrograms/roller bottle of infected cells. All viral DNA was stored at approximately 10 °C.

Example 3

DNA Sequencing

DNA sequencing was performed by flourescent labeled dideoxy sequencing reactions using ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit with Amplitaq DNA polymerase, FS (Perkin-Elmer; per manufacturer's instructions) and electrophoresed on an Perkin-Elmer/Applied Biosystems automated DNA sequencer Model 373A according to manufacturer's instructions. Reactions using both the dGTP mixes and the dITP mixes were performed to clarify areas of compression. Alternatively, compressed areas were resolved on formamide gels. Templates were double-stranded plasmid subclones or single stranded M13 subclones, and primers were either made to the vector just outside the insert to be sequenced, or to previously obtained sequence. Sequence obtained was assembled and compared using DNAStar software.

Example 4

Molecular Biological Techniques

Techniques for the manipulation of bacteria and DNA, including such procedures as digestion with restriction endonucleases, gel electrophoresis, extraction of DNA from gels, ligation, phosphorylation with kinase, treatment

with phosphatase, growth of bacterial cultures, transformation of bacteria with DNA, and other molecular biological methods are described by J. Sambrook et al., *Molecular Cloning A Laboratory Manual* Second Edition, Cold Spring Harbor Press, 1989 and *Current Protocols in Molecular_Biology* (1992) John Wiley & Son's, Inc. Except as noted, these were used with minor variation.

Example 5

Polymerase Fill-In Reaction

DNA was resuspended in buffer containing 50 mM Tris pH 7.4, 50 mM KCl, 5 mM $MgCl_2$, and 400 micromolar each of the four deoxynucleotides. Ten units of Klenow DNA polymerase (BRL) were added and the reaction was allowed to proceed for 15 minutes at room temperature. The DNA was then phenol extracted and ethanol precipitated as above.

Example 6

Cloning With The Polymerase Chain Reaction

The polymerase chain reaction (PCR) was used to introduce restriction sites convenient for the manipulation of various DNAs. The procedures used are described by M. A. Innis et al., *PCR Protocols A Guide to Methods and Applications*, 84-91, Academic Press, Inc., San Diego, 1990.). In general, amplified fragments were less than 500 base pairs in size and critical regions of amplified fragments were confirmed by DNA sequencing. The primers used in each case are detailed in the descriptions of the construction of homology vectors below.

Example 7

Preparation Of Infected Cell Lysates

A confluent monolayer of secondary chicken embryo fibroblasts cells in a 25 cm^2 flask or a 60 mm petri dish was infected with 100 microliters of virus sample. After cytopathic effect was complete, the medium and cells were

harvested and the cells were pelleted at 3000 rpm for 5 minutes in a clinical centrifuge. The cell pellet was resuspended in 250 microliters of disruption buffer (2% sodium dodecyl sulfate, 2% ß-mercapto-ethanol). The samples were sonicated for 30 seconds on ice and stored at -20 °C.

Example 8

Western Blotting Procedure

Samples of lysates and protein standards were run on a polyacrylamide gel according to the procedure of Laemnli, U.K. (1970) Nature 277:680. After gel electrophoresis the proteins were transferred and processed according to Sambrook *et al.* (1989). The primary antibody was diluted 1:100 with 5% non-fat dry milk in Tris-sodium chloride, and sodium azide (TSA: 6.61g Tris-HCl, 0.97g Tris-base, 9.0g NaCl and 2.0g Sodium Azide per liter H_2O). The secondary antibody was alkaline phosphatase conjugated and diluted 1:1000 with TSA.

Example 9

cDNA Cloning Procedure

cDNA cloning refers to the methods used to convert RNA molecules into DNA molecules following state of the art procedures. Applicants' methods are described in (U. Gubler and B. J Hoffman, Gene 25, 263-269). Bethesda Research Laboratories (Gaithersburg, Md.) have designed a cDNA Cloning Kit that is very similar to the procedures used by applicants, and contains a set of reagents and protocols that may be used to duplicate our results.

For cloning virus mRNA species, a host cell line sensitive to infection by the virus was infected at 5-10 plaque forming units per cell. When cytopathic effect was evident, but before total destruction, the medium was removed and the cells were lysed in 10 mls lysis buffer (4M guanidine thiocyanate, 0.1% antifoam A, 25 mM sodium citrate pH 7.0, 0.5% N-lauryl sarcosine, 0.1M β-metcaptoethanol). The cell lysate was poured into a sterilized Dounce homogenizer and homogenized on ice 8-10 times until the solution was

homogenous. For RNA purification, 8 mls of cell lysate were gently layered over 3.5 mls of CsCl solution (5.7M CsCl, 25 mM sodium citrate pH 7.0) in Beckman SW41 centrifuge tube. The samples were centrifuged for 18 hrs at 20 °C at 36000 rpm in a Beckman SW41 rotor. The tubes were put on ice and the supernatants from the tubes were carefully removed by aspiration to leave the RNA pellet undisturbed. The pellet was resuspended in 400 microliters glass distilled water, and 2.6 mls of guanidine solution (7.5M guanidine-HCL, 25 mM sodium citrate pH 7.0, 5 mM dithiothreitol) were added. The 0.37 volumes of 1M acetic acid were added, followed by 0.75 volumes of cold ethanol and the sample was put at -20 °C for 18 hrs to precipitate RNA. The precipitate was collected by centrifugation in a Sorvall centrifuge for 10 min at 4 °C at 10000 rpm in an SS34 rotor. The pellet was dissolved in 1.0 ml distilled water, recentrifuged at 13000 rpm, and the supernatant saved. RNA was re-extracted from the pellet 2 more times as above with 0.5 ml distilled water, and the supernatants were pooled. A 0.1 volume of 2M potassium acetate solution was added to the sample followed by 2 volumes of cold ethanol and the sample was put at -20 °C for 18 hrs. The precipitated RNA was collected by centrifugation in the SS34 rotor at 40 °C for 10 min at 10000 rpm. The pellet was dissolved in 1 ml distilled water and the concentration taken by absorption at A260/280. The RNA was stored at -70 °C.

mRNA containing polyadenylate tails (poly-A) was selected using oligo-dT cellulose (Pharmacia #27 5543-0). Three mg of total RNA was boiled and chilled and applied to the 100 mg oligo-dT cellulose column in binding buffer (0.1M Tris pH 7.5, 0.5M LiCl, 5 mM EDTA pH 8.0, 0.1% lithium dodecyl sulfate). The retained poly-A RNA was eluted from the column with elution buffer (5 mM Tris pH 7.5, 1 mM EDTA pH 8.0, 0.1% sodium dodecyl sulfate). This mRNA was reapplied to an oligo-dT column in binding buffer and eluted again in elution buffer. The sample was precipitated with 200 mM sodium acetate and 2 volumes cold ethanol at -20 °C for 18 hrs. The RNA was resuspended in 50 microliters distilled water.

Ten micrograms poly-A RNA was denatured in 20 mM methyl mercury hydroxide for 6 min at 22 °C. β-mercaptoethanol was added to 75 mM and the

sample was incubated for 5 min at 22 °C. The reaction mixture for first strand cDNA synthesis in 0.25 ml contained 1 micrograms oligo-dT primer (P-L Biochemicals) or 1 micrograms synthetic primer, 28 units placental ribonuclease inhibitor (Bethesda Research Labs #5518SA), 100 mM Tris pH 8.3, 140 mM KCl, 10 mM $MgCl_2$, 0.8 mM DATP, dCTP, dGTP, and dTTP (Pharmacia), 100 microcuries ^{32}P-labeled dCTP (New England Nuclear #NEG-013H), and 180 units AMV reverse transcriptase (Molecular Genetics Resources #MG 101). The reaction was incubated at 42 °C for 90 min, and then was terminated with 20 mM EDTA pH 8.0. The sample was extracted with an equal volume of phenol/chloroform (1:1) and precipitated with 2M ammonium acetate and 2 volumes of cold ethanol -20 °C for 3 hrs. After precipitation and centrifugation, the pellet was dissolved in 100 microliters distilled water. The sample was loaded onto a 15 ml G-100 Sephadex column (Pharmacia) in buffer (100 mM Tris pH 7.5, 1 mM EDTA pH 8.0, 100 mM NaCl). The leading edge of the eluted DNA fractions was pooled, and DNA was concentrated by lyophilization until the volume was about 100 microliters, then the DNA was precipitated with ammonium acetate plus ethanol as above.

The entire first strand sample was used for second strand reaction which followed the Gubler and Hoffman *(supra)* method except that 50 micrograms/ml dNTP's, 5.4 units DNA polymerase I (Boerhinger Mannheim #642-711), and 100 units/ml *E. coli* DNA ligase (New England Biolabs #205) in a total volume of 50 microliters were used. After second strand synthesis, the cDNA was phenol/chloroform extracted and precipitated. The DNA was resuspended in 10 microliters distilled water, treated with 1 micrograms RNase A for 10 min at 22 °C., and electrophoresed through a it agarose gel (sigma Type II agarose) in 40 mM Tris-acetate pH 6.85. The gel was stained with ethidium bromide, and DNA in the expected size range was excised from the gel and electroeluted in 8 mM Tris-acetate pH 6.85. Electroeluted DNA was lyophilized to about 100 microliters, and precipitated with ammonium acetate and ethanol as above. The DNA was resuspended in 20 microliters water.

Oligo-dC tails were added to the DNA to facilitate cloning. The reaction contained the DNA, 100 mM potassium cacodylate pH 7.2, 0.2 mM dithiothreitol, 2 mM $CaCl_2$, 80 micromoles dCTP, and 25 units terminal deoxynucleotidyl transferase (Molecular Genetic Resources #S1001) in 50 microliters. After 30 min at 37 °C., the reaction was terminated with 10 mM EDTA, and the sample was phenol/chloroform extracted and precipitated as above.

The dC-tailed DNA sample was annealed to 200 ng plasmid vector pBR322 that contained oligo-dG tails (Bethesda Research Labs #5355 SA/SB) in 200 microliters of 0.01M Tris pH 7.5, 0.1M NaCl, 1 mM EDTA pH 8.0 at 65 °C for 2 min and then 57 °C for 2 hrs. Fresh competent *E. coli* DH-1 cells were prepared and transformed as described by D. Hanahan, *Molecular Biology* 166, 557-580, 1983, using half the annealed cDNA sample in twenty 200 microliters aliquots of cells. Transformed cells were plated on L-broth agar plates plus 10 micrograms/ml tetracycline. Colonies were screened for the presence of inserts into the ampicillin gene using Ampscreen (Bethesda Research Labs #5537 UA), and the positive colonies were picked for analysis.

Example 10

DNA Transfection For Generating Recombinant Marek's Disease Virus

The method is based upon the polybrene-DMSO procedure of Kawai and Nishizawa, Mol. and Cell. Biol. 4:1172-1174 (1984) with the following modifications. Generation of recombinant MDV virus is dependent upon homologous recombination between MDV viral DNA and the plasmid homology vector containing the desired foreign DNA flanked by the appropriate herpesvirus cloned sequences. Transfections were carried out in 6 cm plates (Corning plastic) of 50% confluent primary chick embryo fibroblast (CEF) cells. The cells were plated out the day before in CEF growth media (1X F10/199, 5% fetal calf serum, 2% glutamine, 1% non-essential amino acids, and 2% penicillin/streptomycin) containing 4 micrograms/ml polybrene (stock 4 mg/ml in 1X HBSS). For cotransfections into CEF cells, 5 micrograms of intact MDV DNA, and suspended in 1 ml of CEF media containing 30 micrograms/ml polybrene (stock 4 mg/ml in

1X HBSS). The DNA-polybrene suspension (1 ml) was then added to a 6 cm plate of CEF cells from which the media had been aspirated, and incubated at 39 °C for 30 minutes. The plates were rocked periodically during this time to redistribute the inoculum. After this period, 4 ml of CEF growth media was added directly to wash plate, and incubated an additional 2.5 hours at 39 °C. At this time, the media was removed from each plate, and the cells shocked with 2 ml of 30% DMSO (Dimethyl Sulfoxide, J. T. Baker Chemical Co., Phillipsburg, NJ) in 1X HBSS for 4 minutes at room temperature. The 30% DMSO was carefully removed and the monolayers washed once with 1X HBSS at room temperature. The cells were then incubated at 39 °C after the addition of 5 mls of CEF growth media. The next day, the media was changed to remove any last traces of DMSO and to stimulate cell growth. Cytopathic effect from the virus becomes apparent within 6 days. Generation of a high titer stock (80%-90% CPE) can usually be made within 1 week from this date. MDV stock samples were prepared by resuspending the infected cells in CEF growth media containing 20% fetal calf serum, 10% DMSO and stored at -70 °C.

Example 11

Screen For Recombinant Marek's Disease Virus Expressing ß-Galactosidase (Bluogal And CPRG Assays) Or ß-Glucuronidase (X-Gluc Assay)

When the *E. coli* ß-galactosidase (lacZ) marker gene was incorporated into a recombinant virus the plaques containing the recombinants were visualized by one of two simple methods. In the first method, the chemical Bluogal™ (Life Sciences Technology, Bethesda, MD) was incorporated (200 µg/ml) into the agarose overlay during the plaque assay, and plaques expressing active ß-galactosidase turned blue. The blue plaques were then picked onto fresh CEF cells and purified by further blue plaque isolation. In the second method, CPRG (Boehringer Mannheim) was incorporated (400 µg/ml) into the agarose overlay during the plaque assay, and plaques expressing active ß-galactosidase turned red. The red plaques were then picked onto fresh cells CEF cells and purified by

further red plaque isolation. In both cases viruses were typically purified with three to four rounds of plaque purification.

When the *E. coli* ß-glucuronidase (uidA) marker gene was incorporated into a recombinant virus the plaques containing the recombinants were visualized by using the chromogenic substrate, X-β-D-gluUA CHX (X-GLUC; 5-Bromo-4-chloro-3-indoxyl-β-D-glucuronic acid, cyclohexylammonium salt; Biosynth AG; Switzerland) was incorporated (200 µg/ml) into the agarose overlay during the plaque assay, and plaques expressing active ß-glucuronidase turned blue. The blue plaques were then picked onto fresh CEF cells and purified by further blue plaque isolation.

Example 12

Screen For Foreign DNA sequence Expression In Recombinant Marek's Disease Virus Using Black Plaque Assays

To analyze expression of foreign antigens expressed by recombinant MDV viruses, monolayers of CEF cells are infected with recombinant MDV, overlaid with nutrient agarose media and incubated for 4-5 days at 39 °C. Once plaques have developed, the agarose overlay is removed from the dish, the monolayer rinsed 1X with PBS, fixed with 100% methanol for 10 minutes at room temperature and the cells air dried. After re-hydrating the plate with PBS, the primary antibody is diluted to the appropriate dilution with PBS and incubated with the cell monolayer for 2 hours to overnight at room temperature. Unbound antibody is then removed from the cells by washing three times with PBS at room temperature. An alkaline phosphatase conjugated secondary antibody is diluted with PBS and incubated with the cells for 2 hours at room temperature. Unbound secondary antibody is then removed by washing the cells three times with PBS at room temperature. Next, the monolayer is rinsed in color development buffer (100mM Tris pH 9.5/100mM NaCl/5mM $MgCl_2$), and then incubated 10 minutes to overnight at room temperature with freshly prepared substrate solution (0.3 mg/ml Nitro Blue tetrazolium+0.15 mg/ml 5-Bromo-4-Chloro-3-Indolyl Phosphatase in color development buffer.) Finally, the reaction is stopped by

replacing the substrate solution with TE (10 mM Tris, pH7.5/1mM EDTA). Plaques expressing the correct antigen will stain black.

Example 13

Plasmid Having Foreign DNA Inserted Into Open Reading Frame UL54.5 of Marek's Disease Virus Type 1

The plasmid 440-29.2 was constructed for the purpose of inserting foreign DNA into Marek's disease virus type 1 (MDV-1). It comprises the approximately 2596 base pair *Bam*HI "M" genomic fragment of Marek's disease virus type 1 (SEQ ID NO: 1). Three open reading frames within the *Bam*HI "M" fragment are the herpesvirus homologs of the UL54 (ICP27) ORF (Position 1 to 1353 of SEQ ID NO: 1), a previously unidentified ORF hence named UL54.5 (Position 2187 to 1483 of SEQ ID NO: 1) and UL55 (Position 2459 to 2593 of SEQ ID NO: 1) (see Figures 1 and 2). DNA sequence (1492 base pairs) spanning the MDV-1 UL54 (ICP27) gene has been published (Virology 1994 Oct; 204(1):242-50). MDV ICP27, based on significant similarity to HSV-1 ICP27, is 1419 nucleotides long and encodes 473 amino acids (54.5 kDa). The UL55 ORF is truncated and contained only the first 49 amino acids of this protein. A potential ORF located between UL54 and UL55 was identified. This ORF is 705 base pairs long and potentially encodes a protein of 235 amino acids in size. BLAST searches of protein data bases using the UL54.5 amino acid sequence identified a similar gene in MDV-2 (Virology 1994 May 15;201(1):142-6). It was noted that the MDV-2 gene shared low homology with the equine herpes virus type 1 the first open reading frame (ORF-1). The similarity index of the UL54.5 proteins from MDV-1 and MDV-2 is 63 percent over a consensus length of 170 amino acids. UL54.5 is transcribed in the opposite orientation relative to UL54 and UL55.

The UL54.5 ORF is non-essential and foreign DNA is inserted within this ORFs or in the intergenic region between the ORFs. Any restriction site within this region is useful as an insertion site for foreign DNA. A restriction enzyme site within this region which is not unique is altered by insertion of a DNA linker which converts the site to a unique restriction enzyme recognition sequence.

Preferably the restriction enzyme site used for insertion of foreign DNA is an *Nde*I site at approximately nucleotide 2173 within the 2596 base pair *Bam*HI "M" genomic fragment. The insertion site is within the UL54.5 ORF between amino acids 4 and 5 of the open reading frame. The plasmid vector was derived from an approximately 3045 base pair *Bam*HI restriction fragment of pSP64 (Promega). Fragment 1 is an approximately 2596 base pair *Bam*HI "M" genomic fragment of Marek's disease virus type 1. Plasmid 440-29.2 was used to make homology vectors for insertion of foreign DNA in recombinant Marek's disease virus.

Example 14

Plasmid Having Infectious Laryngotracheitis Virus DNA Inserted Into Open Reading Frame UL54.5 of Marek's Disease Virus Type 1

The plasmid 980-85.01 was constructed for the purpose of inserting foreign DNA into recombinant Marek's disease virus type 1 (MDV-1). It incorporates the ILT virus gD and gI genes and the *E. coli* ß-galactosidase (lacZ) marker gene flanked by MDV-1 DNA. These genes were inserted into a unique *Nde*I site converted to a *Pac*I site using synthetic DNA linkers. Upstream of the foreign DNA sequence is an approximately 422 base pair fragment of MDV DNA. Downstream of the foreign DNA sequences is an approximately 2174 base pair fragment of MDV DNA. Direction of transcription of the ILT virus gD and gI genes and the *E. coli* ß-galactosidase (lacZ) marker gene is opposite the direction of transcription of the MDV UL54 and UL55 ORFs. When the plasmid is used according to the DNA Transfection For Generating Recombinant Marek's Disease Virus 11) and Screen For Recombinant Marek's Disease Virus Expressing ß-Galactosidase (Bluogal And CPRG Assays) Or ß-Glucuronidase (X-Gluc Assay), (Example 11), a virus containing DNA coding for the foreign DNA sequences will result. The ILTV gD and gI genes are expressed as overlapping transcripts from their own respective endogenous ILTV promoters, and share their own endogenous polyadenylation signal, and the *E. coli* ß-galactosidase (lacZ) marker gene is transcribed from the PRV gX promoter and is followed by the PRV gX poly adenylation signal.

Plasmid 980-85.1 was constructed utilizing standard recombinant DNA techniques by joining restriction fragments from the following sources with the synthetic DNA sequences. The ILT gD, gI, and the *E. coli* ß-galactosidase (lacZ) marker gene was inserted as a cassette into the homology vector 440-29.2 at the unique *Nde*I site which was converted to a *Pac*I site using synthetic DNA linkers. The plasmid vector was derived from an approximately 3045 base pair *Hind*III restriction fragment of pSP64 (Promega). Fragment 1 is an approximately 418 base pair *Bam*HI to *Nde*I restriction sub-fragment of the MDV *Bam*HI restriction fragment M. Fragment 2 is an approximately 3556 base pair *Sal*I to *Hind*III restriction subfragment of the ILTAsp718I genomic fragment #8 (10.6 kilobases). Fragment 3 is an approximately 413 base pair *Sal*I to *Bam*HI restriction subfragment of the PRV *Bam*HI restriction fragment #10. Fragment 4 is an approximately 3010 base pair *Bam*HI to *Pvu*II restriction fragment of plasmid pJF751 (11). Fragment 5 is an approximately 754 base pair *Nde*I to *Sal*I restriction subfragment of the PRV *Bam*HI restriction fragment #7. Fragment 6 is an approximately 2174 base pair *Nde*I to *Bam*HI restriction sub-fragment of the MDV *Bam*HI restriction fragment M.

Example 15

Plasmid Having Newcastle Disease Virus DNA Inserted Into Open Reading Frame UL54.5 of Marek's Disease Virus Type 1

The plasmid 980-46.74 was constructed for the purpose of inserting foreign DNA into recombinant Marek's disease virus Type 1 (MDV-1). It incorporates an *E. coli* ß-galactosidase (lacZ) marker gene and Newcastle disease virus (NDV) F gene flanked by MDV DNA. The *E. coli* ß-galactosidase (lacZ) marker gene and NDV F gene were inserted as a cassette into the homology vector 440-29.2 (Example 13) into the unique *Nde*I site converted to a *Pac*I site using synthetic DNA linkers.

Upstream of the foreign DNA sequences is an approximately 422 base pair fragment of MDV DNA. Downstream of the foreign DNA sequences is an approximately 2174 base pair fragment of MDV DNA. Direction of transcription

of the *E. coli* ß-galactosidase (lacZ) marker gene and the NDV F gene is opposite the direction of transcription of the MDV UL54 and UL55 ORFs. When the plasmid is used according to the DNA Transfection For Generating Recombinant Marek's Disease Virus (Example 10) and Screen For Recombinant Marek's Disease Virus Expressing ß-Galactosidase (Bluogal And CPRG Assays) Or ß-Glucuronidase (X-Gluc Assay), (Example 11), a virus containing DNA coding for the foreign DNA sequences will result. The NDV F gene is under the control of the HCMV immediate early promoter and is followed by the HSV TK poly adenylation signal. The *E. coli* ß-galactosidase (lacZ) marker gene is transcribed from the PRV gX promoter and is followed by the PRV gX poly adenylation signal.

Plasmid 980-85.1 was constructed utilizing standard recombinant DNA techniques by joining restriction fragments from the following sources with the synthetic DNA sequences. The *E. coli* ß-galactosidase (lacZ) marker gene and the NDV F gene were inserted as a cassette into the homology vector 440-29.2 (Example 13) at the unique *Nde*I site which was converted to a *Pac*I site using synthetic DNA linkers. The plasmid vector was derived from an approximately 3045 base pair *Hind*III restriction fragment of pSP64 (Promega). Fragment 1 is an approximately 418 base pair *Bam*HI to *Nde*I restriction sub-fragment of the MDV *Bam*HI restriction fragment M. Fragment 2 is an approximately 413 base pair *Sal*I to *Bam*HI restriction subfragment of the PRV *Bam*HI restriction fragment #10. Fragment 3 is an approximately 3010 base pair *Bam*HI to *Pvu*II restriction fragment of plasmid pJF751. Fragment 4 is an approximately 754 base pair *Nde*I to *Sal*I restriction subfragment of the PRV *Bam*HI restriction fragment #7. Fragment 5 is an approximately 1191 base pair *Pst*I to *Ava*II restriction subfragment of the HCMV genomic *Xba*I E fragment. Fragment 6 is an approximately 1812 base pair *Bam*HI to *Pst*I restriction fragment of the full length NDV F cDNA clone (B1 strain). Fragment 7 is an approximately 784 base pair *Sma*I to *Sma*I restriction subfragment of the HSV *Bam*HI restriction fragment Q. The last fragment is an approximately 2174 base pair *Nde*I to *Bam*HI restriction sub-fragment of the MDV *Bam*HI restriction fragment "M".

Example 16

Plasmid Having Foreign DNA Inserted Into Open Reading Frame UL43 of Marek's Disease Virus Type 1

The plasmid 962-80.1 was constructed for the purpose of inserting foreign DNA into Marek's disease virus type 1 (MDV-1). It comprises the approximately 3212 base pair *Sac*I to *Bgl*II subfragment contained within the *Bam*HI "B" genomic fragment of Marek's disease virus type 1 (SEQ ID NO: 2). Three open reading frames within the 3212 base pair *Sac*I to *Bgl*II subfragment are the herpesvirus homologs of the UL42 ORF (Position 35 to 1144 of SEQ ID NO: 2), UL43 (Position 1304 to 2566 of SEQ ID NO: 2) and UL44 (gC) (Position 2786 to 3220 of SEQ ID NO: 2) (see Figures 3 and 4). DNA sequence (732 base pairs) spanning the MDV-1 UL44 (gC) gene and promoter region have been published (Virus Genes 3, 125-137 (1989)). DNA sequence of MDV-2 UL42, UL43, and UL44 genes have been published (*J. Gen. Virol.* 79 (Pt 8), 1997-2001 (1998). The similarity index of the UL42 proteins from MDV-1 and MDV-2 is 74 percent over a consensus length of 369 amino acids. The similarity index of the UL43 proteins from MDV-1 and MDV-2 is 54 percent over a consensus length of 401 amino acids. The similarity index of the UL44 proteins from MDV-1 and MDV-2 is 45 percent over a consensus length of 145 amino acids. The MDV-1 UL43 ORF is non-essential and foreign DNA is inserted within this ORFs or in the intergenic region between the ORFs. Any restriction site within this region is useful as an insertion site for foreign DNA. A restriction enzyme site within this region which is not unique is altered by insertion of a DNA linker which converts the site to a unique restriction enzyme recognition sequence. Preferably the restriction enzyme site used for insertion of foreign DNA is an *Xho*I site at approximately nucleotide 1386 within the 3212 base pair *Sac*I to *Bgl*II subfragment contained within the *Bam*HI "B" genomic fragment of Marek's disease virus type 1. The insertion site is within the UL43 ORF between amino acids 29 and 30 of the open reading frame. The plasmid vector was derived from an approximately 3045 base pair *Bam*HI restriction fragment of pSP64 (Promega).

Fragment 1 is an approximately 3212 base pair *Sac*I to *Bgl*II subfragment contained within the *Bam*HI "B" genomic fragment of Marek's disease virus type 1. Plasmid 962-80.1 was used to make homology vectors for insertion of foreign DNA in recombinant Marek's disease virus.

Example 17

Plasmid Having Infectious Laryngotracheitis Virus DNA Inserted Into Open Reading Frame UL43 of Marek's Disease Virus Type 1

The plasmid 980-85.22 was constructed for the purpose of inserting foreign DNA into recombinant Marek's disease virus type 1 (MDV-1). It incorporates the ILT virus gD and gI genes and the *E. coli* ß-galactosidase (lacZ) marker gene flanked by MDV-1 DNA. These genes were inserted into a unique *Xho*I site converted to a *Pac*I site using synthetic DNA linkers. Upstream of the foreign DNA sequence is an approximately 1386 base pair fragment of MDV DNA. Downstream of the foreign DNA sequences is an approximately 1826 base pair fragment of MDV DNA. Direction of transcription of the ILT virus gD and gI genes and the *E. coli* ß-galactosidase (lacZ) marker gene is the same direction of transcription as the MDV UL42 and UL43 ORFs. When the plasmid is used according to the DNA Transfection For Generating Recombinant Marek's Disease Virus (Example 10) and Screen For Recombinant Marek's Disease Virus Expressing ß-Galactosidase (Bluogal And Cprg Assays) Or ß-Glucuronidase (X-Gluc Assay), (Example 11) a virus containing DNA coding for the foreign DNA sequences will result. The ILTV gD and gI genes are expressed as overlapping transcripts from their own respective endogenous ILTV promoters, and share their own endogenous polyadenylation signal, and the *E. coli* ß-galactosidase (lacZ) marker gene is transcribed from the PRV gX promoter and is followed by the PRV gX poly adenylation signal.

Plasmid 980-85.22 was constructed utilizing standard recombinant DNA techniques by joining restriction fragments from the following sources with the synthetic DNA sequences. The ILT gD, gI, and the *E. coli* ß-galactosidase (lacZ) marker gene was inserted as a cassette into the homology vector 962-80.1 at the

unique *Xho*I site which was converted to a *Pac*I site using synthetic DNA linkers. The plasmid vector was derived from an approximately 3045 base pair *Hind*III restriction fragment of pSP64 (Promega, Madison, WI). Fragment 1 is an approximately 1386 base pair *Sac*I to *Xho*I restriction subfragment contained within the *Bam*HI "B" genomic fragment of Marek's disease virus type 1. Fragment 2 is an approximately 3556 base pair *Sal*I to *Hind*III restriction subfragment of the ILTAsp718I genomic fragment #8 (10.6 kilobases). Fragment 3 is an approximately 413 base pair *Sal*I to *Bam*HI restriction subfragment of the PRV *Bam*HI restriction fragment #10. Fragment 4 is an approximately 3010 base pair *Bam*HI to *Pvu*II restriction fragment of plasmid pJF751 (11). Fragment 5 is an approximately 754 base pair *Nde*I to *Sal*I restriction subfragment of the PRV *Bam*HI restriction fragment #7. Fragment 6 is an approximately 1826 base pair *Xho*I to *Bgl*II restriction subfragment contained within the *Bam*HI "B" genomic fragment of Marek's disease virus type 1.

Example 18

Recombinant Marek's Disease Virus Type 1 Having Infectious Laryngotracheitis Virus DNA Inserted Into Open Reading Frame UL43

S-MDV-006 is a Marek's disease type 1 virus that expresses three foreign DNA sequences. The genes for ILT virus gD and gI and the *E. coli* ß-galactosidase (lacZ) marker gene were inserted into a unique *Pac*I restriction site (*Pac*I linkers inserted into a unique *Xho*I restriction site in the UL43 ORF of the approximately 3212 base pair *Sac*I to *Bgl*II subfragment contained within the *Bam*HI "B" genomic fragment of Marek's disease virus type 1. The ILTV gD and gI genes are expressed as overlapping transcripts from their own respective endogenous ILTV promoters, and share their own endogenous polyadenylation signal, and the *E. coli* ß-galactosidase (lacZ) marker gene is transcribed from the PRV gX promoter and is followed by the PRV gX poly adenylation signal. S-MDV-006 was derived from S-MDV-002 (MDV-1; CVI-988 Rispens). This was accomplished utilizing the homology vector 980-85.22 and virus S-MDV-002 in the DNA Transfection For Generating Recombinant Marek's Disease Virus

procedure (Example 10). The co-transfection stock was screened by the ß-glucuronidase (X-Gluc Assay) (Example 11). The final result of red plaque purification was the recombinant virus designated S-MDV-006. This virus was assayed for ß-galactosidase expression, purity, and insert stability by multiple passages monitored by the blue plaque assay as described in Example 11. After the initial four rounds of purification, all plaques observed are blue indicating that the virus is pure, stable, and expressing the foreign DNA sequences.

S-MDV-006 was assayed for expression of ILT specific antigens using the Screen For Foreign DNA Sequence Expression In Recombinant Marek's Disease Virus Using Black Plaque Assays (Example 12). Polyclonal chicken anti-ILT serum (SPAFAS) was shown to react specifically with S-MDV-006 plaques and not with S-MDV-002 negative control plaques. All S-MDV-006 observed plaques reacted with the polyclonal serum indicating that the virus was stably expressing the ILT foreign DNA sequences. The assay described here were carried out in CEF cells, indicating that CEF cells would be a suitable substrate for the production of MDV recombinant vaccines.

S-MDV-006 is a recombinant Marek's disease type 1 virus expressing the ILT gD and gI proteins and is useful as a vaccine in ILT infection. S-MDV-006 is also useful for expression of the ILT gD and gI proteins.

Example 19

Plasmid Having Newcastle Disease Virus DNA Inserted Into Open Reading Frame UL43 of Marek's Disease Virus Type 1

The plasmid 980-60.02 was constructed for the purpose of inserting foreign DNA into recombinant Marek's disease virus Type 1 (MDV-1). It incorporates an *E. coli* ß-galactosidase (lacZ) marker gene and Newcastle disease virus (NDV) F gene flanked by MDV DNA. The *E. coli* ß-galactosidase (lacZ) marker gene and NDV F gene were inserted as a cassette into the homology vector 962-80.1 into the unique *Xho*I site converted to a *Pac*I site using synthetic DNA linkers.

Upstream of the foreign DNA sequence is an approximately 1386 base pair fragment of MDV DNA. Downstream of the foreign DNA sequences is an approximately 1826 base pair fragment of MDV DNA. Direction of transcription of the *E. coli* ß-galactosidase (lacZ) marker gene and the NDV F gene is the same direction of transcription as the MDV UL42 and UL43 ORFs. When the plasmid is used according to the DNA Transfection For Generating Recombinant Marek's Disease Virus (Example 10) and Screen For Recombinant Marek's Disease Virus Expressing ß-Galactosidase (Bluogal And Cprg Assays) Or ß-Glucuronidase (X-Gluc Assay), (Example 11), a virus containing DNA coding for the foreign DNA sequences will result. The NDV F gene is under the control of the HCMV immediate early promoter and is followed by the HSV TK poly adenylation signal. The *E. coli* ß-galactosidase (lacZ) marker gene is transcribed from the PRV gX promoter and is followed by the PRV gX poly adenylation signal.

Plasmid 980-85.1 was constructed utilizing standard recombinant DNA techniques by joining restriction fragments from the following sources with the synthetic DNA sequences. The *E. coli* ß-galactosidase (lacZ) marker gene and the NDV F gene were inserted as a cassette into the homology vector 962-80.1 at the unique *Xho*I site which was converted to a *Pac*I site using synthetic DNA linkers. The plasmid vector was derived from an approximately 3045 base pair *Hind*III restriction fragment of pSP64 (Promega).

Fragment 1 is an approximately 1386 base pair *Sac*I to *Xho*I restriction subfragment contained within the *Bam*HI "B" genomic fragment of Marek's disease virus type 1.

Fragment 2 is an approximately 413 base pair *Sal*I to *Bam*HI restriction subfragment of the PRV *Bam*HI restriction fragment #10. Fragment 3 is an approximately 3010 base pair *Bam*HI to *Pvu*II restriction fragment of plasmid pJF751. Fragment 4 is an approximately 754 base pair *Nde*I to *Sal*I restriction subfragment of the PRV *Bam*HI restriction fragment #7. Fragment 5 is an approximately 1191 base pair *Pst*I to *Ava*II restriction subfragment of the HCMV genomic *Xba*I E fragment. Fragment 6 is an approximately 1812 base pair *Bam*HI to *Pst*I restriction fragment of the full length NDV F cDNA clone (B1 strain).

Fragment 7 is an approximately 784 base pair *Sma*I to *Sma*I restriction subfragment of the HSV *Bam*HI restriction fragment Q. The last fragment is an approximately 1826 base pair *Xho*I to *Bgl*II restriction subfragment contained within the *Bam*HI "B" genomic fragment of Marek's disease virus type 1.

Example 20

Recombinant Marek's Disease Virus Type 1 Having Newcastle Disease Virus DNA Inserted Into Open Reading Frame UL43

S-MDV-004 is a Marek's disease type 1 virus that expresses two foreign DNA sequences. The gene for Newcastle disease virus Fusion (F) and the *E. coli* ß-galactosidase (lacZ) marker gene are inserted into a unique *Pac*I restriction site (*Pac*I linkers inserted into a unique *Xho*I restriction site in the UL43 ORF of the approximately 3212 base pair *Sac*I to Bgl II subfragment contained within the *Bam*HI "B" genomic fragment of Marek's disease virus type 1. The NDV F gene is under the control of the HCMV immediate early promoter, and the *E. coli* ß-galactosidase (lacZ) marker gene is transcribed from the PRV gX promoter and is followed by the PRV gX poly adenylation signal. S-MDV-004 is derived from S-MDV-002 (MDV-1; CVI-988 Rispens). This is accomplished utilizing the homology vector 980-60.02 and virus S-MDV-002 in the DNA Transfection For Generating Recombinant Marek's Disease Virus (Example 10). The co-transfection stock was screened by the Screen For Recombinant Marek's Disease Virus Expressing ß-Galactosidase (Bluogal And Cprg Assays) Or ß-Glucuronidase (X-Gluc Assay), (Example 11). The final result of red plaque purification is the recombinant virus designated S-MDV-004. This virus is assayed for ß-galactosidase expression, purity, and insert stability by multiple passages monitored by the blue plaque assay as described in Example 11. After the initial four rounds of purification, all plaques observed are blue indicating that the virus is pure, stable, and expressing the foreign DNA sequences.

S-MDV-004 is assayed for expression of NDV specific antigens using the Screen For Foreign DNA Sequence Expression In Recombinant Marek's Disease Virus Using Black Plaque Assays (Example 12). A monoclonal antibody specific

for NDV F is shown to react specifically with S-MDV-004 plaques and not with S-MDV-002 negative control plaques. All S-MDV-004 observed plaques react with the polyclonal serum, indicating that the virus is stably expressing the NDV F gene. The assay described here is carried out in CEF cells, indicating that CEF cells would be a suitable substrate for the production of MDV recombinant vaccines.

S-MDV-004 is a recombinant Marek's disease type 1 virus expressing the NDV F protein and is useful as a vaccine in NDV infection. S-MDV-004 is also useful for expression of F protein.

Example 21

Plasmid Having Foreign DNA Inserted Into Open Reading FrameUL7 And/Or Between Open Reading Frames UL8 and UL7 of Marek's Disease Virus Type 1

A plasmid is constructed for the purpose of inserting foreign DNA into Marek's disease virus type 1 (MDV-1). It comprises the approximately 7316 base pair subfragment contained within the *Bam*HI "G" genomic fragment of Marek's disease virus type 1 (SEQ ID NO: 3). Five open reading frames within the 7316 base pair subfragment are the herpesvirus homologs of the UL9 ORF (Position 1 to 425 of SEQ ID NO: 3), UL8 (Position 439 to 2748 of SEQ ID NO: 3), UL7 (gC) (Position 3699 to 2782 of SEQ ID NO: 3), UL6 (Position 5704 to 3536 of SEQ ID NO: 3) and UL5 (Position 5772 to 7316 of SEQ ID NO: 3) (see Figures 5 and 6). The area between ORFs UL 8 and UL 7 Position 2749 to 2781 of SEQ ID NO: 3), and the portion of ORF 7 that does not overlap with ORF UL 6 (Position 2782 to 3535 of SEQ ID NO: 3) is nonessential to viral replication and can be used to create mutant and/or recombinant viruses.

Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the inveniton is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.

CLAIMS

1. A recombinant avian herpesvirus comprising a foreign DNA sequence inserted into the UL54.5 open reading frame of a Marek's disease virus (MDV).

2. The recombinant herpesvirus of claim 1, wherein said foreign DNA encodes a polypeptide.

3. The recombinant herpesvirus of claim 2, wherein said polypeptide comprises more than ten amino acids.

4. The recombinant herpesvirus of claim 2, wherein said polypeptide is antigenic.

5. The recombinant herpesvirus of claim 1, wherein said avian herpesvirus comprises Marek's disease virus type 1 (MDV-1).

6. The recombinant herpesvirus of claim 5, wherein said foreign DNA sequence is under control of a herpesvirus promoter located upstream of said foreign DNA sequence and is selected from the group consisting of PRV gX promoter, MDV gB promoter, MDV gA promoter, MDV gD promoter, ILTV gB promoter, ILTV gI promoter, HCMV immediate early promoter and substantially homologous sequences.

7. The recombinant herpesvirus of claim 5, wherein said foreign DNA sequence encodes an antigenic polypeptide from a virus selected from the group consisting of chicken anemia virus, infectious bursal disease, Marek's disease virus, Newcastle disease virus, infectious laryngotracheitis virus, infectious bronchitis virus, and substantially homologous sequences.

8. The recombinant herpesvirus of claim 7, wherein said foreign DNA sequence comprises a DNA sequence encoding an antigenic polypeptide from infectious bursal disease virus selected from the group consisting of VP2, VP3, VP4, and substantially homologous sequences.

9. The recombinant herpesvirus of claim 7, wherein said foreign DNA comprises a DNA sequence encoding an antigenic polypeptide from Marek's disease virus selected from the group consisting of glycoprotein B, glycoprotein D, glycoprotein A, and substantially homologous sequences.

10. The recombinant herpesvirus of claim 7, wherein said foreign DNA comprises a DNA sequence encoding an antigenic polypeptide from Newcastle's disease virus selected from the group consisting of F, HN and substantially homologous sequences.

11. The recombinant herpesvirus of claim 7, wherein said foreign DNA comprises a DNA sequence encoding an antigenic polypeptide from infectious bronchitis virus selected from the group consisting of spike protein, nucleocapsid protein, matrix protein and substantially homologous sequences.

12. A mutant avian herpesvirus comprising a deletion of at least a portion of the UL54.5 open reading frame of a Marek's disease virus (MDV).

13. The mutant herpesvirus of claim 12, wherein said UL54.5 open reading frame is completely deleted.

14. A recombinant avian herpesvirus comprising a foreign DNA sequence inserted into the UL43 open reading frame of Marek's disease virus.

15. The recombinant herpesvirus of claim 14, wherein said foreign DNA encodes a polypeptide.

16. The recombinant herpesvirus of claim 15, wherein said polypeptide comprises more than ten amino acids.

17. The recombinant herpesvirus of claim 15, wherein said polypeptide is antigenic.

18. The recombinant herpesvirus of claim 17, wherein said avian herpesvirus comprises Marek's disease virus type 1 (MDV-1).

19. The recombinant herpesvirus of claim 14, wherein said foreign DNA sequence is under control of a herpesvirus promoter located upstream of said foreign DNA sequence and is selected from the group consisting of PRV gX promoter, MDV gB promoter, MDV gA promoter, MDV gD promoter, ILTV gB promoter, ILTV gI promoter, HCMV immediate early promoter, and substantially homologous sequences.

20. The recombinant herpesvirus of claim 19, wherein said foreign DNA sequence encodes an antigenic polypeptide from a virus selected from the group consisting of chicken anemia virus, infectious bursal disease, Marek's disease virus, Newcastle disease virus, infectious laryngotracheitis virus, infectious bronchitis virus, and substantially homologous sequences.



FIGURE 1


100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2000 2100 2200 2300 2400 2500
UL54 (ICP27)
UL54.5
UL55
MDV Bam HI "M" (2596 bp)
1
1
1353
1483
2187
2454
2596

FIGURE 2



FIGURE 3


200
400
600
800
1000
1200
1400
1600
1800
2000
2200
2400
2600
2800
3000
3200
Bgl II
Sac I
Xho I
SacI-Bgl II (3222 bp)
UL42
UL43
UL44
35
1144
1304
2566
2786
3220

FIGURE 4


TRL
UL
IRL
IRS
US
TRS
UL5
UL6
UL7
UL8
UL9
1.8 kb
1.4 kb
BamHI 'G' (Bg#1)-7.2 kb

FIGURE 5


500 1000 1500 2000 2500 3000 3500 4000 4500 5000 5500 6000 6500 7000
Acc I 7
Apa I 1
Ava I 1
BamH I 2
Bcl I 3
Bgl II 6
BstU I 14
BstX I 1
Cla I 3
Dde I 12
Dpn I 26
Dra I 8
EcoR I 1
Fsp I 2
Hha I 8
Hinc II 7
Hind III 1
Hinf I 28
Hpa I 1
Kpn I 2
Mbo I 26
Mlu I 2
Mnl I 37
Nci I 3
Nco I 2
Nde I 1
Nhe I 1
Nru I 2
Nsi I 6
Pst I 1
Pvu I 2
Sac I 1
Sal I 3
SnaB I 1
Sph I 3
Ssp I 8
Taq I 38
Xba I 2
Xmn I 7
UL9
UL8
UL7
UL6
UL5
1
425
439
2748
2782
3536
5704
5772
7316

FIGURE 6

SEQUENCE LISTING

<110> Schering Corporation

<120> Novel Recombinant and Mutant Herpesviruses

<130> SY0994 PCT

<140>

<141>

<150> US 09/289,254

<151> 1999-04-09

<160> 3

<170> PatentIn Ver. 2.0

<210> 1

<211> 2596

<212> DNA

<213> Marek's Disease Virus 1

<400> 1

ggatcctcct ccgatgaaaa tgccgaagtg actgaaatgg aaacatctgc aaaaacggct 60
aataacaaga atgaagtttt attcgcgcca ccgtgtacgc aggaactttt gaccgaacga 120
ccatctcctg attccaaaaa ttcgcaaggc gacgatgact caaattcaat atatggcaac 180
gtgattcgtg atgctcaaca ctcagcaagt cgatatgcta caaggtgtct tgacaatgca 240
ataccacgga aacgtctacg cttagctaat ttgacagtag attctgcatg catttcccaa 300
actaaacggc cgcacggtac aggcaatcgc aaacaatatc acagacgtaa ttttccgatg 360
tcaccgactt cacaagaaaa aattcatcta cgattgcaca accgacttgg atctcggagc 420
gaaaaacagc agcgcagtct aaattacgac cgacgtctgc aagaagggca tcaccgaaga 480
agattctaca gtgagagacg tatttatgat caaaatcata gtcaccatcg tacacacgat 540
atacgggtac cattggaaaa atatagagtt tccagacaac atgatctccc tgtccatgag 600
gaactaaacg aaatacttca aagagagaaa caccgtctgg cctctatttc aaatgagtgt 660
gattttcgcg tttcgagcaa aaatcgatgg gctgccgtat taacattttc aagcaacgcg 720

gagagtacct tatgtggtcc tcagataaca tgggagtatt tattgcatgc gggtccagag 780
ctacgaaaca cgttcgaaat cagacctaga atatcgctac aagcaagtgc agcacgagaa 840
gccgtgttgc gaggtgaaag tttcattgcc gcattaggga gtgctgaaga aactctgtcg 900
tggttaaaac tacatgctgt tttaaagtta cgcctagtaa atcatgaccc gatttttaag 960
accgctggtg cggttttaga taacctcagg ctgaagctcg caccaataat gatgtgtaaa 1020
tatggaacag agaaacgctc catgggggat atgttaagaa gatctgctcc tgaagatata 1080
aacgattcct taactctgtg cttaattttg ttatcgcgca ttcgtcgtgt gatgcatcgc 1140
acatcgggca gcaaatacag ttatatgata gaccctagag gatgtatgat agactatgta 1200
cctggagaat gtatgacaaa tatactacgt tatgtagatg cgcatacgag gagatgttct 1260
gatcccgcat gtaacttgta tatcagctgc acactcatgc ctatttatat ccatggcagg 1320
tatttttact gcaatactct gtttggtatg taaatagtta tctaaaagac atcctatatt 1380
tagtattcta cacaatttct tctgacgata ttactaactc ctctaataaa gttaaataaa 1440
taaacgtctc agatatgtct tgttaaagtg tggttttatt atctatatat caccgacttt 1500
agatacggaa tatgaaaatg atggccctga aattgcacga acagctgtgg tgaagattcc 1560
gtcaaattta catttgaaat ttaagtatat aaattcaggt gatcctataa catcgttaaa 1620
caagctctcg agtagtttaa tgaacgctaa acattgaagt ccaccagggc gatcacaaag 1680
gcagttgact aacatgccat gcgctccagg attgtcgcga actgccgact cgcataaaca 1740
aataatttttt ctcggatctc tcatttccag aaatctacgc gggtccatca gcaatgccgg 1800
ttttattcct ggaacacagt tagacgtaaa ctgctcgaaa actgttttaa gcacaaccgg 1860
gatgtctgca aaagccgatg atgcttcctt ataacagcgc tcagttagaa accataacag 1920
ttcttttggt agtatatttc ttcctagaaa ccatggcgtt cccatcgcta agaaccaagc 1980
atgtgttttc actgtatctt gtccaaagag ccctctattc ggagatgtat gttggagatc 2040
ggatgtccag agtactgctt tatctcgcat agatgaggtc gcagttacaa ttctcccttt 2100
ccagccaccc gtcaacatga tgtttattgg actaccaaca ttggtaatga gtactggtct 2160
ggcgactatt ccatatgcat tagtcattga aatttctcgt ggaatcagcc aaactggaga 2220
atctgcacat ctttattatt cgatgtggaa tgaccatgat cgctttgttg gtctgtaccg 2280
ttagcagaca tattcagagt aatgtcacga agacttaagg gtggctttca tttcaaacct 2340
ggagaacttg tagggttgta tagtcgacag gatgtaggtg gagacatgac gtctacaaag 2400
agacatccta taaggccatt cctgcagaaa cttataggtt tataccagag acgactcaat 2460
ggcagcaggg gcgatgtcat cgtcaacatt ggctcaaata ccgaatgtat accaagttat 2520
tgatcccttа gcgattgata catcgtcgac atctacaaaa cgattactgg atgaacctgt 2580
accacacata ggatcc 2596

<210> 2
<211> 3222
<212> DNA

<213> Marek's Disease Virus 1

<400> 2

gagctcctct aattccgata accggctgtt gtcaatggca ggaataacta tgggcagcga 60
acacatgtat gatgatacaa cgttcccaac aaacgatcct gagtcttcat ggaaaattgt 120
tttggctgga gagaaattta tgacagcatc ggctgcatta aaaacaatag taggttgcgt 180
gaagaaccca ttaattacat ttagcgacga cggactgatg atacagggca cggtttgcgg 240
tcaacgtatg tttgttccta tcgattgtac ttcattcagt gaatatgaat ggcgcgggcc 300
cacagcaata ttcctagctc ttaccgattc tagacgtacc ctcttagatg cattcaaatg 360
cgataagaaa aaagtagtag aagtttgttt tacctttcga ggagaaccac catgccgaca 420
tctaacacaa accgtcacat atgcaaatga tggatgctca ttttcgagta caatcgtcaa 480
atatgaatta tggagcgcat ccatcatttg tcctcaaaaa actccagatg ctacattttc 540
attaaacaaa caacaattga gcaaaattct aactgtagct gcaaaagtac aacatgaaga 600
attgatcttt gctttgaaag ctgaaggagg tttttatgcc ggaacgattt gtgatgtgat 660
aagttttgat atagatggaa gcgcaatggt ccaatatccc tataatgcaa caagtcatgc 720
ttcgtcagcc ctcatcgtgg catgtgggaa gaaaaaaaca aataaaagta tagctgtaac 780
tgcatacggc agcgggaaac ctttctgcct tgcactggaa gatactaacg catttagaaa 840
tgtcgtgcaa aaaattaaaa cgggagccgc tggggcggat ttgggatttt atacaacgtg 900
tgatccaccg atgctgtgtg tacgtccgca cgtgtttgga agtcccacgg cattcctgtt 960
ttgcaattca gactgtatgt caatatacga attggaagaa gtgagtgcag tatctggagc 1020
aataaagtcg aaacgcatca gcggatattt ccccaaagta tcaaatatcg gctcccggaa 1080
acggggacca tcttcacccc ccttcgaacg agaagggaaa cttgccaaag ttatcaacca 1140
atgagacttt cgtgaggacc tgtaagtatg tcatggagtg ggagggttca tttatattgc 1200
atgtaagcct tatagaggat acaccagaaa ctcatagttg tgccaattca aacgacaccg 1260
ttcatctgaa ctacaaaaca gaataccgct atcaaattgg aacatggatt ctgtcaacaa 1320
ctcatcatta cctccgtctt atacaaccac tggtagaaca tatggacatt gtctgcaaat 1380
gctcacatgc ctcgagccac cgtgtacaac aacaaatgga aacggaatat caaacaatcg 1440
atgtctaaaa tgtatcgtag taaccatgtg ttcgatattc tccattgcag ctcatttggc 1500
tatcaccctg tcatgtataa ccttgattca atttattgac caaaaaatta tctatataaa 1560
ctgtactatt tatgctatca ccggatttct aattgccttc atcgtgcgtc ttacgataaa 1620
atcgtcagaa gtgctgacat caattggcaa accggcacaa tttatatttg ctttaatctc 1680
atccatagca gatacgctta ttacaagaaa tatgttaatt gacagtaatc catcttatgt 1740
aaaaatattg agagcaatag agatgacatc tttgatgtgc tttgtcatgc ttggagcatt 1800
cattgcatcc taccactatg tctgcttggc aacgtctgga gatttaactt ggaaagctgg 1860
gtttttgata ttgaccgccg gaacaattat cggaatatca gctccatatg gaaacatttc 1920
ctccctattc ggatttctat ttctatatac tatattagcc ataaacgttg taagggatgc 1980

aagtaaagca ctgatgaata catgctatta tcgcatttgt cgtgcaacga ctctacgcca 2040
tccctctcgc ctcggctgcg gtcgtatgtc ctcgactcaa gatgtcaatg caacgcatga 2100
agaagccata tcaagcgcag atacgattga tggtcagatt cctatggtag ttatgagcca 2160
cgcgacaggc gtattaattc cagttgttat tgccttgcag aggtacatga caaaggagac 2220
tgttagtttg acatcgactg atatgttaca gggagtctgt ggcgttttag tgggggcgag 2280
tgtttcaata tttatcccgt cacgtcgcga cgaaagttta tcccgtccaa ttatcatttt 2340
attgtctata ataggagcaa tggccattac tttggcaggt tttggtttgg tactcgggcc 2400
aactttattt tccgcatgtg cagcagcttt gtcatgttat acctgcatta atataaggaa 2460
tgcaaataag ggaattaaac aattagcagc tgcctatgta gtgaaatcta tactgggatt 2520
tatcataact agtttacttg tttgtatatt agtagcgcta tcttgaccaa atcgttgttc 2580
acatcttggc catatacgta ttgatcgttg tttcgaaccg cgaataaaac tttcatacat 2640
actaaacgat ggagttgtgt tttatgagcg ttgaaaacaa aggtaccatc ggtttaaaac 2700
taagttgcat atcgtaatcc acaaaaatca ttttatacat catcccgaag agacaccaaa 2760
cgtaaccctc tacatatctt ccctcatgct cacgccgcgt gtgttacgag ctttggggtg 2820
gactggactc tttttttttgc ttttatctcc gagcaacgtc ctaggagcca gccttagccg 2880
ggatctcgaa acacccccat ttctatcctt tgatccatcc aacatttcaa ttaacggcgc 2940
gcctttaact gaggtacctc atgcaccttc cacagaaagt gtgtcaacaa attcggaaag 3000
taccaatgaa cataccataa cagaaacgac gggcaagaac gcatacatcc acaacaatgc 3060
gtctacggac aagcaaaatg cgaacgacac tcataaaacg cccaatatac tctgcgatac 3120
ggaagaagtt tttgttttcc ttaacgaaac gggaagattt gtttgtactc tcaaagtcga 3180
ccccccctcg gatagtgaat ggtccaactt tgttctagat ct 3222

<210> 3
<211> 7316
<212> DNA
<213> Marek's Disease Virus 1

<400> 3
ggatccaaaa ttctcaccat agtcaaccat ccactcagag ccatgcagtg tctttattta 60
aagtcacatg ggagattctc ttcggactcc gcctcacaaa gagtacaaca acatttccgg 120
gtagaacaaa agtaaagaat ttacggaagg cggagataga agctctgtta gacggagcgg 180
gtattgatag aacgtcatgc aaaactcaca aggatctcta caccctcttg atgaaaagca 240
agtcattatt tcgcaatatg cgctatgata ttcgacgccc gaagtggtac gacctattaa 300
gatctcgttt agacaaagag ttgggtatat atcatgatct ggtagatttg gaatctgtgt 360
tggcggaaat tccgtcagca ctctggccac gcgtagaagg tgctgtagat tttcatcgtt 420
tataattatt ggaaccgaat gcgtcaaacc atatcaacga tggcagcatc gtcaaaaact 480

aatatgatgc agataatgcg aggatgtatt tgttatacga ctgtgtatag aatttggact 540
aataaaaatc gtaccgaagg actcactgca ttatgctatc tacttttttcg aaatacatgc 600
ggtcaatact cggcacaata ttctacagta aacctctccg gaaaatccat ggctaaactt 660
tggggcctga acccagatat gattactgat acaatgttag caggtatgac caattccgca 720
tctgtaaccg gattatggcc atcttgccct tcggaccaac acatgctatg gaaagcgtta 780
ctcactacga ctctagcaaa attaagacac cgtctgggat atcatgctta ttatacacct 840
gtaaccatct atatcgacag tcaaactggg ttagttacag cttgcgaacc ggtatcagga 900
gaaagatcta tccctcgccc cggattattg aaaacggacg gaatgatcag cgttgaagag 960
tcatgtctta tctcgactgc catgaagcat gcggagggtg caccctggc ccacattaaa 1020
ctgtcagccc ttaaacgtac ccgtcaaatt ccagagtttg acatgagaat tgaaatacag 1080
acaaaagaag aacgatttct tcgtgaatat aaaaaagtga acagcccata taagaaattt 1140
aaatgtgaca acaattcaaa tacaatattt aaagttgtgg acaatacgtt ggttttagac 1200
catttacagc ctccggtaag agcattgtct ctcgtcccca cgtcttttga ctgtttagtt 1260
acaacccccg ccgaattttc gcttgttgct ctattagcta cttatgcaaa atggcatgag 1320
aaactatact cttgtgataa cgaatcgaca aatattttgg tacctatatt aatgtacatc 1380
ggtcctgaaa ctaatccccg aggtgaagat gtagactata gttgtatcat cgggtttcca 1440
ggctggccaa ttgtgaaatc ctccaccgca aatcaaacag ctataaaaga tgcgatagat 1500
gcctatgtag atacggacgg cctgtggcca ttagctgggc ctagaacatt tcatctatta 1560
gctccgtggt ctcccgaaaa ccatccgttc cccatgatag acacgtccca cattttatct 1620
gtacattcta cggatatcag acacaaagca gccgatgaat ggacaacagg acgaataact 1680
tgtattttac gcgatccgac cctaatagaa aatgcagcga tcgccaaatt tgacttcagt 1740
gcatttttg caactttata tcttggcctc tttcccaccc attctcgatt acatgatgta 1800
gtgaaggcaa ggttaaaacg cgaaaaacca tggctcaaac ggcctatctt agaatttgga 1860
ggtttgctta aaaaacttaa tgaagatgta tatcaatcta tcatctccat tgggaatcat 1920
attagtattg aggttgaggc taccgcatct tctcttatgt ttgctccctg tacttacatc 1980
aaagacggga tgtggggcac attcatggac aaatcaaaaa atgtcccacg tccgccaatg 2040
gatgatgagc gcgactttaa tatattgcgg aacgcgtgtg ctgagagcgc taataatttc 2100
gccgcgacaa tagggctgca gtttcccgac gaaattctac tagatctgcg tttggaaggc 2160
atttatacac atgcaatgtc atggaatgcc aactgttact ggctgtggaa taaatccaat 2220
catcataagg attttgtagg gtttcctaac caacctagat ttgcaagtta tgcaaaacat 2280
ggtctttcta ctcttctgga aaaaatatgc ataagcaatg atactgacga atctcttcaa 2340
acggttcggg aaaaaaccca tgaagtgttc gaagagctgc tctccatagc gtttgatcac 2400
cgcagtgatg tgtccttttg gagctgtcct acagaattgt atgatgacac tcaatacatt 2460
gctgctctag gaatgaaggc agcagctaga tttgatacca gtggtttcaa tcgcgagact 2520
gtccaaactg tgacagcaga tggaaaaata gtttctgtta catgctctct ttttgaagga 2580
gaaataatcc ttcctgccat agattgtatc gattatatga aaccaatact ggctgcattt 2640

tctagattat taatcaatgt tctgtcttct aaatgggaca atgttaacag agatgatttt 2700
acgttcgata ttgagtcgta taggtttatg tttattaata ataaatgaca taaagttctg 2760
tttgcattat attttttatt ttcatttttg gtatgtgtga aataaacatt cctccccct 2820
taaattgttt cgtccataat gccaccaatc acatattata tcacttaacc atttttgttg 2880
gaaagctcca ttcaacaagc ctttgttgat tacgatagaa cattttcctc gcgtagaaac 2940
tggtacctgg aacgcctcac ctaaattgtt acattcatat aaagatatta acacatcaca 3000
aactccatta gtagaactta aatgtttgta tataatgtag tgaggaagaa catgattact 3060
atcgaatgga ctaatagaac tcagttccat tagggtattt agtaaccaag tatttgtaat 3120
acataaaaat ctacgcattt tgcgcatcgg cgttactgtc gaccatgcat atttcagaaa 3180
actttgaagt tgaacatata gtgacgggtc ggatgagctg acgttccggt tttccaaata 3240
tgagatgagc aaacaaaggg caaaatccaa aggttctgct ggatggtacg acacaaatct 3300
atattttaga agtgggggcg gtattcctat cgttttcacc acgtcctcca tagccgtgag 3360
aatcataaat atgaaacctt tgaacgcagg gttagctata cattgcgtgt aatatatatc 3420
actgcttatt tcttcgtcag tttcagttcc tgctaaaatc aaatgtaagc gtctaatgca 3480
gttcgctact cgaagtttat agacggagac acctgtaaac tgggtgggga ctccattaat 3540
ctctctgact tccatcatca tcctcgccat tggttgtcga ctgagttctt cgataatcgc 3600
gtctcgattc cctgttccat ctatggcgtt tataaccaga gcgtctagag tatcgctcac 3660
gtcgagagga tggagaatgg aagtcatttc ttcttccatg atggccgtca ggcaaatctt 3720
ctgcctcgcg ttgccttccc gaattatttc tgacgaggaa atatttcgcg atggctcttt 3780
ttacatcggc attaaagatt agtgctaaat catccagata aacgtgaata cgtgtctttt 3840
caaataccga attgcataac tcctcctctg atttataaac ctcgtgattc gttactattg 3900
gcccaatatc ataaatattc aatacggaaa aaaagtaagg agcgagtagt aaagttatcg 3960
cactgttcga gtaggaaatt gaaacctcat gaccctgatt attggtagct cgtgtcaatt 4020
taaaacatcg cagcatttcc tgttcccaaa gttcagaaag tcttttcaag tctacatcat 4080
acgcaggtat atatcttgac tgaaaactat tagcaacata ggaatcatca tccataactt 4140
cacctacatc aataacatca tgtttaaggt cacgcgccaa agtttctaat gtcgggctgt 4200
actgagaatt gcccatatca gtgtgtgcct gttttgagat aagatgttca gtacgaactc 4260
tgtcgagttc taattctttg gaacaaagtt ttgctagcaa atctttattg gcagctttca 4320
agccttcaac ggtgttaaac aatttattca catagccttc tagcatctcg tttatacttg 4380
ttacaacaga cgaatggaat gcatcccgaa ttttaatggt attacgtcga gtttcctcgg 4440
ttgtagaaga ttgtgcccga ttggattggc cgaaacccgg ctgagatgta tcgatcgaag 4500
cagcatccaa taaatgcccg ctcgtttctt ccaaatagtc tcgaaccgtg tcagtaatat 4560
ctcccacatg acgcatacct ttaagaccaa taatcagttt gactaatctg gatgcagcag 4620
aacttgctgc attttctggt tgatctccca aaactttgtc gatgactcgt tgggcccctg 4680
ctacccccct acatccatca tcgcgttttg caataagaac ttttacagga gccgtgttga 4740
caagtcgaca taaagttgca tgttgacgca aatcatgaca ttcaataatc tccttgtata 4800

ttcgttgcat tggcgaatca aaaataactc cgccatcgtt cattactggc ctccagataa 4860
caatacattc cccacgctca ccactcaata tatcctttac ccgaagttct cgtttaaaga 4920
aattatattc tatcaatgtt ctgtcatatt cgagaatgct tactgccgac atcgaattcg 4980
ataagtaatt cacaatttgt tttccacgag ccataacact atcgacgact cgaagtctac 5040
tggaggcatc atgaaatgcc cagtttggaa aaacagttga tctgcctgcg catgtaggta 5100
tagaacttgt tgcccttgca gaacgatcat gtctaacaac tggaacgata ccaaggcaac 5160
aaatccaatc tatatatttg gaaaaactgg aagtgtttat attggccgta gtaaagcaag 5220
aaattagctg acgagccaaa tttatcaatg tagtttgcag agttttgcgc catgttacaa 5280
aaacattttc tgctaccttа acagcttctg cttcactatg cataccatat gttctggcaa 5340
gtttttttgc tgacatccca cgcatgtcag catgccgtat ccaatcattt tttagatcgt 5400
catatctaac cgcatccagg ctaagggtga gaatagtatt ttgaatctgt cgaattgcgg 5460
tttctgtaga tcttacggag ttatatatac cctggccatc agtatatcct aatcgacctg 5520
cgaggatctc cttaaacatc cgtgtctgac gagtaggatg gatcacaatc cactgattct 5580
ccatacactg ttttgatgag acgttgttaa aagtatctcg ttgcgacata accgattcga 5640
agtccggatg attaattttt ctactattta aatcgtaagg cgctcttcga tcatagccat 5700
ccattacaag aaatacgaca cgcctctaaa ataattcaag aaaaatttta atttttgcga 5760
gtctattgaa aatgtcacag gaatcgaatg acttattttg cgaagcgacc tatttaaatt 5820
ttaccgccat gcatggaata caatctataa ttactcgtgt aagagctctt gcggacgcga 5880
cgctgagcga tgaattgatt ccaccgttat cctattttat agaagcttcg aatcatgaaa 5940
accctgtaga attagaagca cgagacttgc cattcgctgt ttatttgata agtggcaatg 6000
cgggatctgg aaagagcaca tgcatacaaa cattatcaga gattttggat tgcattatta 6060
ctggtacaac aaaagttgca tctcaaaaca tatattgcaa actcagtaat tcctatacat 6120
cgccacatat aaacactata ttccaggaat ttgggtttaa aggcaaccat gttcaagcca 6180
atttgggtaa atggcaatat gtatgttcga ccagtccacc tacaatgaaa gaattacaaa 6240
aaaaggatat tgtatattat tgggaagtcc tgtccgatat aacgaaaagt atgctgaaag 6300
ttttggattc ggagacaggt ccagggaaat ttgatgtaat acggacatta gaagatctgc 6360
tgggaaaacc tagaggaaac ttgtcttgga tgactttcgg gatacatgga tcactgccat 6420
catttacacg cagtaatata atcatcatcg atgaagccgg attgttgggg aaatatttac 6480
ttacggctat tgtatactgt tggtggctta ccaatgccgt gtatcgtact ccacaatata 6540
aaagagggtt aaaaccagta ttaatatgtg tcgggtcgcc tacacaaaca agttcattgg 6600
aatcgacatt tgaacatagc aaactgaggt gtaatgtaag aataagcgaa aatattctga 6660
cttatattat atgcaatcaa acattacgat catatttaga cttatccaat aattgggcaa 6720
tatttattaa taataaacgc tgtacagaac ccgaatttgg agatcttctc aaaacattgg 6780
aatatggact tcctataacg gaggagcatg cccgaatggc agataacttt gttgttccgg 6840
aagcatttat caataatccg gcgaacctac ctggctggac acgtttatat tcatctcata 6900
aggaagtcag tacatatatg agtagattac atgattactt gaaaacctcc ggcaacaata 6960

agtttgtggt gtttactctg cctgcatata cttttataag tttggagaat tttgaacgct 7020
atcgtacggc tgccaatcaa cctcatatta cacttgagaa atggctcaat gtcaatgcgg 7080
ggcgtttgag caactggtca caaagccgtg atcaagacgc aacacaaact agatgcgaaa 7140
ttagaagcca acaaggtctt gcaatctcat gttctgacat aacttacgta ctgaatagtc 7200
aagtggctgt gactacacga cttaggaaat gggttttcgg tttttgcggc acctttgaga 7260
attttttatc tgtcttaaaa gatgactcgt ttataaaaac acacggagaa ggatcc 7316

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 October 2000 (19.10.2000)

PCT

(10) International Publication Number
WO 00/61736 A3

(51) International Patent Classification[7]: C12N 15/38, 15/45, 15/50, A61K 39/255, 39/17, 39/215

(21) International Application Number: PCT/US00/09518

(22) International Filing Date: 7 April 2000 (07.04.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/289,254 9 April 1999 (09.04.1999) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/289,254 (CON)
Filed on 9 April 1999 (09.04.1999)

(71) Applicant *(for all designated States except US)*: SCHERING-PLOUGH LTD. [CH/CH]; Toepferstrasse 5, CH-6004 Lucerne (CH).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: JUNKER, David, E. [US/US]; 6901 Galewood Street, San Diego, CA 92120 (US).

(74) Agents: FOULKE, Cynthia, L. et al.; Schering-Plough Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*

(88) Date of publication of the international search report:
1 February 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: RECOMBINANT AND MUTANT MAREK'S DISEASE VIRUS



(57) Abstract: The present invention provides methods and reagents for inducing active immunity in animals. In particular, the present invention provides recombinant herpesviruses having foreign DNA that are capable of inducing immunity to the herpesvirus and/or the source of the foreigh DNA. The present invention also provides mutant herpesviruses having portions of their genome deleted. Preferably, foreign DNA is introduced, or portions of the genome are deleted, in the UL54.5 open reading frame of avian herperviruses or the UL43 open reading frame of Marek's disease virus.

WO 00/61736 A3

INTERNATIONAL SEARCH REPORT

Intern ial Application No
PCT/US 00/09518

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/38 C12N15/45 C12N15/50 A61K39/255 A61K39/17
A61K39/215

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, PAJ, STRAND, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 05291 A (SYNTRO CORP.) 22 February 1996 (1996-02-22) abstract page 9, line 24 - line 37	1-4, 14-20
A	page 17, line 1 -page 19, line 2 page 19, line 37 -page 33, line 32 page 34, line 8 -page 35, line 26 page 36, line 5 -page 37, line 31 page 103 -page 106; examples 7A,C,8 page 113; example 11A page 119 -page 121; example 12C page 124 -page 140; examples 16-20 SEQ ID NO: 3 page 156 -page 163 SEQ ID NO: 48 page 205 -page 207 page 213 -page 219; claims 1,3-5,32-36 --- -/--	5-13

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
19 October 2000	03/11/2000

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Fuchs, U

1

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Interna al Application No
PCT/US 00/09518

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropnate, of the relevant passages	Relevant to claim No.
A	REN, D. ET AL.: "Identification and Characterization of Marek's Disease Virus Genes Homologous to ICP27 and Glycoprotein K of Herpes Simplex Virus-1" VIROLOGY, vol. 204, no. 1, October 1994 (1994-10), pages 242-250, XP000926007 cited in the application the whole document	1-20
A	TSUSHIMA, Y. ET AL.: "Gene arrangement and RNA transcription of the BamHI fragments K and M2 within the non-oncogenic Marek's disease virus serotype 2 unique long genome region" VIRUS RESEARCH, vol. 60, no. 1, March 1999 (1999-03), pages 101-110, XP000926015 abstract page 103; figure 1B page 104, column 1, line 22 - line 26 page 105; table 1 page 106, column 1, line 3 - line 13 page 107, column 2, line 12 -page 109, column 1, line 4	1-20

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

...ormation on patent family members

Intern ·al Application No
PCT/US 00/09518

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9605291 A	22-02-1996	US 5961982 A	05-10-1999
		US 5965138 A	12-10-1999
		AU 711815 B	21-10-1999
		AU 3405395 A	07-03-1996
		CA 2196570 A	22-02-1996
		EP 0776361 A	04-06-1997
		JP 10506782 T	07-07-1998
		US 5853733 A	29-12-1998